UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
47081,Euroclear,Bing API,https://www.moneymarketing.co.uk/news/exclusive-platforms-association-expands-to-46-founding-members/,Exclusive: Platforms Association expands to 46 founding members,The Platforms Association has expanded to 46 founding members  less than two months after it was launched. The founding members comprise of several high-profile firms including Abrdn  Aviva  Aegon  Fidelity ,The Platforms Association has expanded to 46 founding members  less than two months after it was launched.The founding members comprise of several high-profile firms including Abrdn  Aviva  Aegon  Fidelity  Quilter  Scottish Widows and Hargreaves Lansdown  among others.The association was launched at the end of September with the aim of representing and providing a voice to the ¬£1trn investment platform sector.Membership of the association is open to regulated platforms whose primary activities are the settlement  custody and safekeeping of retail investor assets  as well as sub-custodian firms and white-label technology providers.There are also affiliate members drawn from platform consultancies  legal firms and software providers.In addition  related financial and professional services firms  including Alpha FMC  have been appointed as independent strategic partners.Platforms Association CEO Keith Philips said: ‚ÄúSince our launch announcement at the end of September  we‚Äôve been astonished at the rate of our expansion.‚ÄúClearly  this is a sector that wants to cohere and address the issues of the day  which will ultimately benefit customers.‚ÄúWe now have the largest and most recognisable investment platform as members and  just as importantly  those major players that constitute the industry ecosystem have also connected.‚ÄúThe sector now has the opportunity to make further  significant  advancements.‚ÄùChair of the board of directors  David Moffat  added: ‚ÄúAs the breadth and depth of our members shows  platform operators and the wider platform ecosystem are really keen to work together to address the opportunities and challenges facing the sector.‚ÄúWe look forward to working with our members  other trade bodies  the FCA and HM Treasury to the wider benefit of investors  advisors and the industry.‚ÄùThe association has also announced the launch of its Leadership Council in early December.The council  chaired by platform veteran Peter Mann  will set the priority policy focus  from which a market engagement roadmap for 2025 will be rolled out.The association will work to deliver a range of services that directly support the industry covering policy  operational and technological issues.The full list of the founding members is as follows:1. 7IM2. Abrdn3. Addleshaw Goddard4. Aegon5. AJ Bell6. Allfunds7. Alpha FMC8. Altus9. Aviva10. Benchmark11. BNY Pershing12. Boston Consulting Group13. Bravura14. Calastone15. Charles Stanley16. Clearstream17. Davies Group18. Deloitte19. DWF Law20. Equisoft21. Euroclear22. Fidelity23. FIS Platform Securities24. Flagstone25. FNZ26. GBST27. Hargreaves Lansdown28. Intelliflo29. InvestEngine30. Just31. Mobius Life32. Morningstar Wealth33. Nucleus34. Origo35. Platform One36. Quilter37. Scottish Widows38. Seccl39. Simplify Consulting40. Soderberg & Partners41. SS&C Hubwise42. The Lang Cat43. Thistle Initiatives44. Transact45. True Potential46. Wealthtime,neutral,0.01,0.99,0.0,positive,0.85,0.15,0.0,True,English,"['Platforms Association', '46 founding members', 'platform veteran Peter Mann', '¬£1trn investment platform sector', 'recognisable investment platform', 'retail investor assets', 'other trade bodies', 'market engagement roadmap', 'SS&C Hubwise', 'The Lang Cat', 'FIS Platform Securities', 'several high-profile firms', 'white-label technology providers', 'independent strategic partners', 'priority policy focus', 'Boston Consulting Group', 'wider platform ecosystem', 'professional services firms', 'The Platforms Association', 'Platforms Association CEO', 'platform consultancies', 'platform operators', 'Platform One', 'regulated platforms', 'sub-custodian firms', 'legal firms', 'software providers', 'wider benefit', '17. Davies Group', 'Simplify Consulting', 'Scottish Widows', 'Hargreaves Lansdown', 'primary activities', 'related financial', 'Alpha FMC', 'Keith Philips', 'major players', 'significant, advancements', 'David Moffat', 'HM Treasury', 'early December', 'full list', 'Addleshaw Goddard', 'AJ Bell', 'BNY Pershing', 'Charles Stanley', 'DWF Law', 'Mobius Life', 'Thistle Initiatives', 'True Potential', 'industry ecosystem', '46 founding members', 'affiliate members', 'launch announcement', 'Leadership Council', 'technological issues', 'Abrdn', 'Aviva', 'Aegon', 'Fidelity', 'Quilter', 'others', 'September', 'aim', 'voice', 'Membership', 'custody', 'safekeeping', 'addition', 'expansion', 'day', 'customers', 'largest', 'opportunity', 'Chair', 'board', 'directors', 'breadth', 'depth', 'shows', 'opportunities', 'challenges', 'FCA', 'investors', 'advisors', 'range', 'operational', '7IM', 'Allfunds', 'Altus', 'Benchmark', 'Bravura', 'Calastone', 'Clearstream', 'Deloitte', 'Equisoft', 'Euroclear', 'Flagstone', 'FNZ', '26. GBST', 'Intelliflo', 'InvestEngine', 'Nucleus', 'Origo', 'Seccl', 'Soderberg', 'Transact', 'Wealthtime', '2025', '12.', '23.']",2024-11-20,2024-11-20,moneymarketing.co.uk
47082,Clearstream,Bing API,https://www.moneymarketing.co.uk/news/exclusive-platforms-association-expands-to-46-founding-members/,Exclusive: Platforms Association expands to 46 founding members,The Platforms Association has expanded to 46 founding members  less than two months after it was launched. The founding members comprise of several high-profile firms including Abrdn  Aviva  Aegon  Fidelity ,The Platforms Association has expanded to 46 founding members  less than two months after it was launched.The founding members comprise of several high-profile firms including Abrdn  Aviva  Aegon  Fidelity  Quilter  Scottish Widows and Hargreaves Lansdown  among others.The association was launched at the end of September with the aim of representing and providing a voice to the ¬£1trn investment platform sector.Membership of the association is open to regulated platforms whose primary activities are the settlement  custody and safekeeping of retail investor assets  as well as sub-custodian firms and white-label technology providers.There are also affiliate members drawn from platform consultancies  legal firms and software providers.In addition  related financial and professional services firms  including Alpha FMC  have been appointed as independent strategic partners.Platforms Association CEO Keith Philips said: ‚ÄúSince our launch announcement at the end of September  we‚Äôve been astonished at the rate of our expansion.‚ÄúClearly  this is a sector that wants to cohere and address the issues of the day  which will ultimately benefit customers.‚ÄúWe now have the largest and most recognisable investment platform as members and  just as importantly  those major players that constitute the industry ecosystem have also connected.‚ÄúThe sector now has the opportunity to make further  significant  advancements.‚ÄùChair of the board of directors  David Moffat  added: ‚ÄúAs the breadth and depth of our members shows  platform operators and the wider platform ecosystem are really keen to work together to address the opportunities and challenges facing the sector.‚ÄúWe look forward to working with our members  other trade bodies  the FCA and HM Treasury to the wider benefit of investors  advisors and the industry.‚ÄùThe association has also announced the launch of its Leadership Council in early December.The council  chaired by platform veteran Peter Mann  will set the priority policy focus  from which a market engagement roadmap for 2025 will be rolled out.The association will work to deliver a range of services that directly support the industry covering policy  operational and technological issues.The full list of the founding members is as follows:1. 7IM2. Abrdn3. Addleshaw Goddard4. Aegon5. AJ Bell6. Allfunds7. Alpha FMC8. Altus9. Aviva10. Benchmark11. BNY Pershing12. Boston Consulting Group13. Bravura14. Calastone15. Charles Stanley16. Clearstream17. Davies Group18. Deloitte19. DWF Law20. Equisoft21. Euroclear22. Fidelity23. FIS Platform Securities24. Flagstone25. FNZ26. GBST27. Hargreaves Lansdown28. Intelliflo29. InvestEngine30. Just31. Mobius Life32. Morningstar Wealth33. Nucleus34. Origo35. Platform One36. Quilter37. Scottish Widows38. Seccl39. Simplify Consulting40. Soderberg & Partners41. SS&C Hubwise42. The Lang Cat43. Thistle Initiatives44. Transact45. True Potential46. Wealthtime,neutral,0.01,0.99,0.0,positive,0.85,0.15,0.0,True,English,"['Platforms Association', '46 founding members', 'platform veteran Peter Mann', '¬£1trn investment platform sector', 'recognisable investment platform', 'retail investor assets', 'other trade bodies', 'market engagement roadmap', 'SS&C Hubwise', 'The Lang Cat', 'FIS Platform Securities', 'several high-profile firms', 'white-label technology providers', 'independent strategic partners', 'priority policy focus', 'Boston Consulting Group', 'wider platform ecosystem', 'professional services firms', 'The Platforms Association', 'Platforms Association CEO', 'platform consultancies', 'platform operators', 'Platform One', 'regulated platforms', 'sub-custodian firms', 'legal firms', 'software providers', 'wider benefit', '17. Davies Group', 'Simplify Consulting', 'Scottish Widows', 'Hargreaves Lansdown', 'primary activities', 'related financial', 'Alpha FMC', 'Keith Philips', 'major players', 'significant, advancements', 'David Moffat', 'HM Treasury', 'early December', 'full list', 'Addleshaw Goddard', 'AJ Bell', 'BNY Pershing', 'Charles Stanley', 'DWF Law', 'Mobius Life', 'Thistle Initiatives', 'True Potential', 'industry ecosystem', '46 founding members', 'affiliate members', 'launch announcement', 'Leadership Council', 'technological issues', 'Abrdn', 'Aviva', 'Aegon', 'Fidelity', 'Quilter', 'others', 'September', 'aim', 'voice', 'Membership', 'custody', 'safekeeping', 'addition', 'expansion', 'day', 'customers', 'largest', 'opportunity', 'Chair', 'board', 'directors', 'breadth', 'depth', 'shows', 'opportunities', 'challenges', 'FCA', 'investors', 'advisors', 'range', 'operational', '7IM', 'Allfunds', 'Altus', 'Benchmark', 'Bravura', 'Calastone', 'Clearstream', 'Deloitte', 'Equisoft', 'Euroclear', 'Flagstone', 'FNZ', '26. GBST', 'Intelliflo', 'InvestEngine', 'Nucleus', 'Origo', 'Seccl', 'Soderberg', 'Transact', 'Wealthtime', '2025', '12.', '23.']",2024-11-20,2024-11-20,moneymarketing.co.uk
47083,Clearstream,Bing API,https://newjersey.news12.com/officials-wildfire-near-lakewood-country-club-now-75-contained,Officials: Wildfire near Lakewood Country Club now 75% contained,A wildfire near Pine Park and the Lakewood Country Club in Lakewood is now 75% contained  according to the New Jersey Forest Fire Service. Officials say the fire  which began Monday afternoon  has burned 35 acres of land. Clearstream Road has reopened after previously being closed due to the fire.,A wildfire near Pine Park and the Lakewood Country Club in Lakewood is now 75% contained  according to the New Jersey Forest Fire Service.Officials say the fire  which began Monday afternoon  has burned 35 acres of land.Clearstream Road has reopened after previously being closed due to the fire.No homes are in danger and no evacuation orders were issued.However  the smoke from the fire did cause some golfers to be turned away from the Lakewood Country Club golf course.‚ÄúWe started seeing smoke out there and the smoke got heavier. The fire department came by  police department said we‚Äôve got to shut it down  get everybody off the course ‚Äù said Ted Misa  of Lakewood Country Club.Officials say the Forest Fire Service will remain on the scene to help extinguish the fire.State fire restrictions remain in effect due to the lack of rain and dryness of the ground.The New Jersey Forest Fire Service says that since October  crews have responded to over 500 wildfires. They say that this is more than a 1 300% increase in wildfires over the same time last year.The cause of the fire was not immediately known.,neutral,0.02,0.96,0.02,negative,0.01,0.21,0.78,True,English,"['Lakewood Country Club', 'Officials', 'Wildfire', 'The New Jersey Forest Fire Service', 'Lakewood Country Club golf course', 'State fire restrictions', 'fire department', 'Pine Park', 'Clearstream Road', 'evacuation orders', 'police department', 'Ted Misa', 'same time', 'wildfire', 'Officials', '35 acres', 'land', 'homes', 'danger', 'smoke', 'golfers', 'everybody', 'scene', 'effect', 'lack', 'rain', 'dryness', 'ground', 'October', 'crews', '1,300% increase', 'cause']",2024-11-20,2024-11-20,newjersey.news12.com
47084,Clearstream,Bing API,https://www.msn.com/en-us/weather/topstories/officials-wildfire-near-lakewood-country-club-50-contained-35-acres-burned/vi-AA1uompK,Officials: Wildfire near Lakewood Country Club 50% contained  35 acres burned,Clearstream Road is closed  but there are no structures being threatened at this time. Comcast will announce the spinoff of cable networks Wednesday  sources say,Clearstream Road is closed  but there are no structures being threatened at this time. Comcast will announce the spinoff of cable networks Wednesday  sources say,negative,0.0,0.11,0.89,neutral,0.04,0.83,0.13,True,English,"['Lakewood Country Club', 'Officials', 'Wildfire', '35 acres', 'Clearstream Road', 'cable networks', 'structures', 'time', 'Comcast', 'spinoff', 'sources']",2024-11-19,2024-11-20,msn.com
47085,Deutsche Boerse,Bing API,https://www.crypto-news-flash.com/ethereum-staking-now-accessible-in-21shares-core-etp/,Ethereum Staking Now Accessible in 21Shares Core ETP,Shares adds Ethereum staking to its Core ETP  simplifying staking access for European investors and boosting DeFi engagement.,21Shares introduces Ethereum staking in its Ethereum Core ETP  enhancing accessibility for European investors.Ethereum ETFs see growing adoption as innovative tax benefits and dual-access trust structures attract investor interest.Switzerland‚Äôs 21Shares has added Ethereum staking capabilities to its Ethereum Core ETP  which is already popular with European investors.The product is currently listed on numerous main exchanges  including the SIX Swiss Exchange  Deutsche B√∂rse Xetra  and Euronext Amsterdam  having been renamed the Ethereum Core Staking ETP with this upgrade.This growth lets investors all throughout Europe access Ethereum staking advantages without having to lock their money straight on the blockchain.Unlock new earning potential! üåü Staking is now available in our 21Shares Ethereum Core Staking ETP (ETHC). With a low TER and the added benefits of staking rewards  ETHC offers even more value. Visit our website for more info:https://t.co/LGXXdTLw8M pic.twitter.com/tuq86LHnps ‚Äî 21Shares (@21Shares) November 19  2024Simplifying Staking: Unlocking Ethereum Yields with EaseAn additional income source for investors is staking  the technique of locking cryptocurrency assets to run blockchain systems. Currently averaging about 3.17%  Ethereum‚Äôs staking yield offers a consistent flow of returns while still exposing one to the underlying asset. Through including staking capability into its Ethereum Core ETP  21Shares lets investors easily get these yields.This creativity fits the approach of 21Shares on streamlining digital asset investment. The company claims that the ETP is among the most reasonably priced solutions available on the market since it has just a 0.21% administration fee. Moreover  the staking feature makes it more competitive by combining simple access to Ethereum with possible yield generation.Including stakes within its Ethereum Core ETP shows how dedicated the business is to providing innovative ideas in a fast-changing industry. 21Shares is lowering obstacles and encouraging more general adoption of Ethereum‚Äôs decentralized features by allowing staking through an exchange-traded commodity.This acquisition highlights the growing curiosity in Ethereum staking as well as the larger change among established financial players toward blockchain technology adoption.On the other hand  CNF previously reported that increased investor interest following U.S. election results drove a record-breaking $515 million weekly inflow for Ethereum ETFs. Another major participant in the ETF market  Monochrome  has unveiled creative Ethereum ETFs with tax benefits.Their dual-access trust system is an attractive choice for investors looking for both profitability and flexibility in the expanding Ethereum market since it lets CGT-free transactions possible.Meanwhile  as of writing  ETH is swapped hands at about $3 103.90  moving ranging in the last 7 days  but still in a bullish structure in a 14.38% raise over the last 30 days.Recommended for you:,neutral,0.01,0.99,0.0,positive,0.78,0.21,0.0,True,English,"['21Shares Core ETP', 'Ethereum', 'Deutsche B√∂rse Xetra', 'U.S. election results', 'record-breaking $515 million weekly inflow', '21Shares Ethereum Core Staking ETP', 'dual-access trust structures', 'numerous main exchanges', 'SIX Swiss Exchange', 'new earning potential', 'additional income source', 'dual-access trust system', 'CGT-free transactions possible', 'digital asset investment', 'possible yield generation', 'Ethereum Core ETP', 'creative Ethereum ETFs', 'innovative tax benefits', 'blockchain technology adoption', 'expanding Ethereum market', 'staking yield', 'underlying asset', 'innovative ideas', 'growing adoption', 'added benefits', 'Simplifying Staking', 'staking feature', 'general adoption', 'investor interest', 'Euronext Amsterdam', 'low TER', 'cryptocurrency assets', 'blockchain systems', 'consistent flow', 'priced solutions', '0.21% administration fee', 'simple access', 'changing industry', 'decentralized features', 'exchange-traded commodity', 'growing curiosity', 'larger change', 'financial players', 'other hand', 'major participant', 'ETF market', 'attractive choice', 'last 7 days', 'bullish structure', 'last 30 days', 'Ethereum Yields', 'European investors', 'accessibility', 'Switzerland', 'capabilities', 'product', 'upgrade', 'growth', 'advantages', 'money', 'ETHC', 'rewards', 'value', 'website', 'info', 'LGXXdTLw8M', 'tuq86LHnps', 'November', 'Ease', 'technique', 'returns', 'capability', 'creativity', 'approach', 'company', 'stakes', 'business', 'obstacles', 'acquisition', 'CNF', 'Monochrome', 'profitability', 'flexibility', 'writing', 'hands', '14.38% raise']",2024-11-20,2024-11-20,crypto-news-flash.com
47086,EuroNext,NewsApi.org,https://www.finextra.com/pressarticle/103250/linedata-introduces-structured-finance-capability,Linedata introduces structured finance capability,Linedata (Euronext Paris: LIN)  a global provider of asset management and credit technology  data  and services  announces the launch of its structured finance offering.,Linedata (Euronext Paris: LIN)  a global provider of asset management and credit technology  data  and services  announces the launch of its structured finance offering.0Integrated with Linedata Ekip360  it simplifies the management of complex structured finance structures for investment banks and credit institutions. The entire value chain is covered in a unified solution. Its broad scope connects all participants via an open syndication process  enables the management of contracts and accounting and even the monitoring of waivers and covenants.This powerful and scalable software platform increases operational efficiency and accelerates the optimization of financing processes. Thanks to its multi-all solution capability  it enables effective management of all parties involved in the contract (borrowers  agent  participants  etc.)  and integrates management dashboards providing summary or detailed information in real time. All these features aim to meet the current challenges of the sector such as the digitalization of processes  artificial intelligence and ever-increasing operational efficiency.‚ÄúWith this new offering  our customers benefit from an integrated and modern solution for the management of their structured finance. The platform provides a complete view of the portfolio and allows users to manage the entire structured finance lifecycle. Our goal is to simplify our customers‚Äô day-to-day operations  while enabling them to increase efficiency and develop their business  particularly through white-label deployment. All features are integrated into the Linedata Ekip360 platform  whose unique configuration and customization capabilities help meet industry expectations ‚Äù said Bertrand Cocagne  Chief Technology and Innovation Officer at Linedata Lending & Leasing.With its AI-powered workflows  modern and customizable interface  simplified configuration and extensive reporting capabilities  Linedata Ekip360 is positioned as a unique high-performance solution:Augmented workflow: Linedata has integrated artificial intelligence to accelerate the power of workflow. The ‚ÄúDigital Assistant‚Äù offers predictive actions based on the choices of other users for the same type of file  thus avoiding errors and speeding up processes.Ergonomics and customization: The application offers a contextual search bar  allowing considerable productivity gains for users. In addition  the interface can be fully and easily customized  increasing the accessibility of functions that are essential to each customer‚Äôs business.Real-time reporting: Business Intelligence features provide access to a wide range of customizable charts and graphs  enabling customers to monitor their business  portfolio  or even identify customers with large amounts under management.Integration: The solution‚Äôs full API stack enables easy integration with the customer‚Äôs ecosystem  including CRM solutions  credit repositories  and due diligence tool providers. These integrations offer a simple  direct and reliable journey to users.Structured finance is now available to all business lines covered by Linedata Ekip360  offering a complete and flexible response to manage any type of financial product: structured finance  corporate credit  leasing  equipment lending  consumer credit  car financing  long-term leasing  inventory financing  including both simple and complex loans  as well as the possibility of extending into other banking activities.,neutral,0.01,0.99,0.0,positive,0.69,0.31,0.0,True,English,"['structured finance capability', 'Linedata', 'due diligence tool providers', 'complex structured finance structures', 'open syndication process', 'contextual search bar', 'considerable productivity gains', 'full API stack', 'entire value chain', 'other banking activities', 'scalable software platform', 'multi-all solution capability', 'extensive reporting capabilities', 'unique high-performance solution', 'structured finance offering', 'increasing operational efficiency', 'Linedata Ekip360 platform', 'Business Intelligence features', 'entire structured', 'complex loans', 'new offering', 'finance lifecycle', 'unique configuration', 'Real-time reporting', 'artificial intelligence', 'unified solution', 'Euronext Paris', 'global provider', 'credit technology', 'investment banks', 'credit institutions', 'broad scope', 'detailed information', 'real time', 'current challenges', 'day operations', 'white-label deployment', 'customization capabilities', 'industry expectations', 'Bertrand Cocagne', 'Chief Technology', 'Innovation Officer', 'AI-powered workflows', 'simplified configuration', 'Digital Assistant', 'predictive actions', 'wide range', 'customizable charts', 'large amounts', 'CRM solutions', 'credit repositories', 'reliable journey', 'flexible response', 'financial product', 'corporate credit', 'equipment lending', 'consumer credit', 'car financing', 'inventory financing', 'Linedata Lending', 'other users', 'modern solution', 'business lines', 'complete view', 'customizable interface', 'Augmented workflow', 'same type', 'easy integration', 'simple, direct', 'asset management', 'effective management', 'management dashboards', 'financing processes', 'long-term leasing', 'services', 'launch', 'participants', 'contracts', 'accounting', 'monitoring', 'waivers', 'covenants', 'powerful', 'optimization', 'parties', 'borrowers', 'agent', 'summary', 'sector', 'digitalization', 'customers', 'integrated', 'portfolio', 'goal', 'choices', 'file', 'errors', 'Ergonomics', 'application', 'addition', 'accessibility', 'functions', 'graphs', 'ecosystem', 'integrations', 'possibility']",2024-11-19,2024-11-20,finextra.com
47087,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983270/0/en/Green-Arrow-selects-Voltalia-to-build-a-power-plant-in-Spain.html,Green Arrow selects Voltalia to build a power plant in Spain,Green Arrow selects Voltalia to build a power plant in Spain    Voltalia (Euronext Paris  ISIN code: FR0011995588)  an international player in...,Green Arrow selects Voltalia to build a power plant in SpainVoltalia (Euronext Paris  ISIN code: FR0011995588)  an international player in renewable energies  announces the signing of a contract with Green Arrow Capital for the Engineering  Procurement and Construction (EPC) and Operation & Maintenance (O&M) of a 135-megawatt solar power plantThe plant will be located in Seville (Andalusia)  in the municipality of Sanlucar la Mayor. Construction will start in 2024  with full commissioning scheduled for 2025. Voltalia will then operate and maintain the plant for at least two years. Covering an area of 169 hectares  the plant will include 192 864 photovoltaic panels with a total capacity of 135 megawatts.Green Arrow Capital is a leading investor focused on renewable energy and other alternative investments in the real economy including Energy & Digital Infrastructure  Private Equity  Private Credit and Real Estate. Founded in 2012 in Italy  Green Arrow Capital is a recognized and rapidly growing player in renewable energy in Spain.Voltalia has been present in Spain for over 15 years. Initially focused on operation and maintenance services  the group now manages 775 megawatts under contract for third party clients.At the same time  Voltalia is also developing a pipeline of future photovoltaic and wind production sites in the country while its subsidiary Helexia  a specialist in self-consumption solar plants for industrial and commercial buildings  holds a portfolio of 51 photovoltaic plants currently under operation for a total 26.7 megawatts.The contract with Green Arrow Capital marks the resumption of major construction contracts in Spain. This year  Voltalia has been particularly active in the Spanish EPC market  in line with the group's strategy to expand its activities to build large scale solar projects for similar clients including IPPs1  funds  and utilities. Spain is one of the most dynamic photovoltaic markets in the world  making it a key focus for Voltalia's growth.Founded in 2005  Voltalia operates 6.7 gigawatts for its customers and has 3.1 gigawatts in operation and under construction in Europe  Africa and Latin America.‚ÄúWe are delighted with this first collaboration with Green Arrow Capital. This new contract confirms the dynamism of Voltalia and Helexia in Spain ‚Äù says S√©bastien Clerc  CEO of Voltalia.Daniele Camponeschi  founder and Chief Investment Officer of Green Arrow Capital  stated: ‚ÄúThe development of this new solar portfolio in Spain highlights the strategic importance of the Iberian market for Green Arrow Capital and follows other successful investments that allow the Group to further strengthen its presence in a key sector like photovoltaics. This initiative also renews our commitment to the energy transition  confirming us as leaders in green investments abroad as well. Having an excellent partner like Voltalia by our side will enable us to ensure the highest quality and sustainability in the execution of the project.‚ÄùNext on the agenda: Q4 2024 Turnover  January 29  2025 (after market close)About Voltalia (www.voltalia.com)Voltalia is an international player in renewable energies. The Group produces and sells electricity from its wind  solar  hydro  biomass and storage facilities. It has 3.1 GW of capacity in operation and under construction  and a portfolio of projects under development with a total capacity of 17.2 GW.Voltalia is also a service provider  supporting its renewable energy customers at every stage of their projects  from design to operation and maintenance.A pioneer in the business market  Voltalia offers a comprehensive range of services to businesses  from the supply of green electricity to energy efficiency services and the local production of its own electricity.With more than 2 000 employees in 20 countries on 3 continents  Voltalia has the capacity to act globally on behalf of its customers.Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 - VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included  amongst others  in the MSCI ESG ratings and the Sustainalytics ratings. Loan Duong  Director of Communications & Investor RelationsEmail : invest@voltalia.comT. +33 (0)1 81 70 37 00 Seitosei ActifinPress Contact: Jennifer JulliaEmail: jennifer.jullia@seitosei-actifin.comT. +33 (0)1 56 88 11 191 Independent Power ProducersAttachment,neutral,0.0,1.0,0.0,positive,0.96,0.04,0.0,True,English,"['Green Arrow', 'power plant', 'Voltalia', 'Spain', 'CAC Mid&Small indices', '1 Independent Power Producers Attachment', 'large scale solar projects', '135-megawatt solar power plant', 'Sanlucar la Mayor', 'self-consumption solar plants', 'S√©bastien Clerc', 'Chief Investment Officer', 'other alternative investments', 'other successful investments', 'Green Arrow Capital', 'third party clients', 'wind production sites', 'MSCI ESG ratings', 'dynamic photovoltaic markets', 'Euronext regulated market', 'new solar portfolio', 'major construction contracts', 'Spanish EPC market', 'energy efficiency services', 'renewable energy customers', 'green investments', '51 photovoltaic plants', 'similar clients', 'local production', 'Sustainalytics ratings', '192,864 photovoltaic panels', 'future photovoltaic', 'renewable energies', 'Iberian market', 'business market', 'energy transition', 'green electricity', 'Euronext Paris', 'ISIN code', 'international player', 'O&M', 'full commissioning', 'leading investor', 'real economy', 'Digital Infrastructure', 'Private Equity', 'Private Credit', 'Real Estate', 'growing player', 'same time', 'commercial buildings', 'key focus', 'Latin America', 'first collaboration', 'Daniele Camponeschi', 'strategic importance', 'key sector', 'excellent partner', 'highest quality', 'Q4 2024 Turnover', 'storage facilities', 'service provider', 'comprehensive range', 'Enternext Tech', 'Loan Duong', 'Investor Relations', 'Press Contact', 'new contract', 'two years', 'total capacity', 'subsidiary Helexia', 'Seitosei Actifin', 'maintenance services', 'total 26.7 megawatts', 'The Group', 'Jennifer Jullia', '15 years', '135 megawatts', '775 megawatts', 'Voltalia', 'Spain', 'signing', 'Procurement', 'Operation', 'Seville', 'Andalusia', 'municipality', 'area', '169 hectares', 'Italy', 'recognized', 'rapidly', 'pipeline', 'country', 'specialist', 'industrial', 'resumption', 'strategy', 'activities', 'funds', 'utilities', 'world', 'growth', '6.7 gigawatts', '3.1 gigawatts', 'Europe', 'Africa', 'dynamism', 'CEO', 'founder', 'development', 'presence', 'photovoltaics', 'initiative', 'commitment', 'leaders', 'side', 'sustainability', 'execution', 'agenda', 'January', 'hydro', 'biomass', '3.1 GW', '17.2 GW', 'stage', 'design', 'pioneer', 'businesses', 'supply', '2,000 employees', '20 countries', '3 continents', 'behalf', 'VLTSA', 'company', 'others', 'Director', 'Communications', 'Email', 'T.']",2024-11-19,2024-11-20,globenewswire.com
47088,EuroNext,NewsApi.org,https://www.etfdailynews.com/2024/11/19/short-interest-in-euronext-otcmktseuxtf-rises-by-6-8/,Short Interest in Euronext (OTCMKTS:EUXTF) Rises By 6.8%,Euronext (OTCMKTS:EUXTF ‚Äì Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 31st  there was short interest totalling 9 400 shares  an increase of 6.8% from the October 15th total of 8 800 sha‚Ä¶,Euronext (OTCMKTS:EUXTF ‚Äì Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 31st  there was short interest totalling 9 400 shares  an increase of 6.8% from the October 15th total of 8 800 shares. Based on an average trading volume of 200 shares  the days-to-cover ratio is currently 47.0 days.Euronext Price PerformanceShares of OTCMKTS EUXTF opened at $109.00 on Tuesday. The firm‚Äôs 50-day moving average price is $110.90 and its two-hundred day moving average price is $102.45. Euronext has a 52-week low of $78.95 and a 52-week high of $114.05.Get Euronext alerts:Euronext Company Profile(Get Free Report)Read MoreEuronext N.V.  together with its subsidiaries  operates securities and derivatives exchanges in Continental Europe  Ireland  and Norway. The company offers a range of exchange and corporate services  including security listings  cash and derivatives trading  and market data dissemination. It also provides listing venues and cash equities trading venues; and various marketplaces  including multilateral trading facilities for investors  broker-dealers  and other market participants to meet directly to buy and sell cash equities  fixed income securities  and exchange traded products.Receive News & Ratings for Euronext Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Euronext and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.03,0.83,0.14,neutral,0.06,0.94,0.0,True,English,"['Short Interest', 'Euronext', 'OTCMKTS', 'EUXTF', 'two-hundred day moving average price', '50-day moving average price', 'FREE daily email newsletter', 'Euronext Price Performance Shares', 'cash equities trading venues', 'average trading volume', 'market data dissemination', 'multilateral trading facilities', 'other market participants', 'concise daily summary', 'Euronext N.V.', 'October 15th total', 'fixed income securities', 'Get Free Report', 'Euronext Company Profile', 'Euronext Daily', 'derivatives trading', 'listing venues', 'email address', 'Euronext alerts', 'short interest', 'October 31st', 'cover ratio', '52-week low', '52-week high', 'derivatives exchanges', 'Continental Europe', 'corporate services', 'security listings', 'various marketplaces', 'related companies', 'MarketBeat.com', 'significant increase', 'latest news', 'OTCMKTS EUXTF', '9,400 shares', '8,800 shares', '200 shares', 'recipient', 'month', 'days', 'Tuesday', 'firm', 'subsidiaries', 'Ireland', 'Norway', 'range', 'investors', 'broker-dealers', 'traded', 'products', 'Ratings', 'analysts']",2024-11-19,2024-11-20,etfdailynews.com
47089,EuroNext,NewsApi.org,https://biztoc.com/x/9626d700fb116da3,EU capital markets integration may be regressing  Commission warns,Delistings on Euronext alone have led to a loss of ‚Ç¨2.3 trillion in market capitalisation since 2015  a new AFME report shows.,Delistings on Euronext alone have led to a loss of ‚Ç¨2.3 trillion in market capitalisation since 2015  a new AFME report shows.This story appeared on euractiv.com   2024-11-19 16:57:30.,negative,0.0,0.24,0.76,negative,0.0,0.11,0.89,True,English,"['EU capital markets integration', 'Commission', 'new AFME report', 'market capitalisation', 'Delistings', 'Euronext', 'loss', 'story', 'euractiv.']",2024-11-19,2024-11-20,biztoc.com
47090,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983753/0/en/GSMA-brings-M360-Eurasia-to-Tashkent-in-partnership-with-Beeline-Uzbekistan-and-Uzbekistan-s-Ministry-of-Digital-Technologies.html,GSMA brings M360 Eurasia to Tashkent in partnership with Beeline Uzbekistan and Uzbekistan‚Äôs Ministry of Digital Technologies,Amsterdam  Dubai and Tashkent  19 November 2024: VEON Ltd. (Nasdaq: VEON  Euronext Amsterdam: VEON)  a global digital operator (‚ÄúVEON‚Äù or the ‚ÄúCompany‚Äù)  today announces that its subsidiary Beeline Uzbekistan has signed a Memorandum of Understanding (MoU) wit‚Ä¶,"Amsterdam  Dubai and Tashkent  19 November 2024: VEON Ltd. (Nasdaq: VEON  Euronext Amsterdam: VEON)  a global digital operator (‚ÄúVEON‚Äù or the ‚ÄúCompany‚Äù)  today announces that its subsidiary Beeline Uzbekistan has signed a Memorandum of Understanding (MoU) with the GSMA and the Ministry of Digital Technologies of the Republic of Uzbekistan to hold M360 Eurasia 2025 in Tashkent on 20-21 May 2025.The signing ceremony took place during M360 MENA 2024 in Doha  Qatar.Presented by the GSMA  M360 is a series of global events that unify the regional mobile ecosystem. The event aims to discover  develop and deliver innovation that serves as the foundation for positive business environments and societal change.‚ÄúWe are pleased to host the mobile ecosystem in Tashkent  a city that has always been at the crossroads of our region  for M360 Eurasia. Uzbekistan has an ambitious digitalization agenda which will not only contribute to the prosperity of our country  but also accelerate the economic growth of our region. We appreciate the role that mobile industry plays in driving this. We would like to thank GSMA and the event‚Äôs host sponsor Beeline Uzbekistan for this partnership which will bring M360 to our capital ‚Äù said Sherzod Shermatov  Minister of Digital Technologies  Republic of Uzbekistan.‚ÄúM360 Eurasia is one of the most significant regional platforms for our ecosystem to come together and explore how we can drive growth with the power of connectivity  digital services and technology. As a Group that has the privilege of driving the digital transformation in dynamic Central and South Asian markets  we are delighted to partner with the GSMA and Uzbekistan‚Äôs Ministry of Digital Technologies to bring this important event to Tashkent  the headquarters of Beeline Uzbekistan‚Äù said Kaan Terzioglu  Beeline Uzbekistan Chairman and VEON Group CEO.""Hosting M360 Eurasia 2025 in Tashkent for the first time marks an important milestone in our commitment to advancing digital transformation in Central Asia. Our thanks to VEON and the Ministry of Digital Technologies of the Republic of Uzbekistan for their support. The event will explore new ways to use mobile connectivity to promote sustainable economic growth and digital inclusion  providing a platform for driving innovation and collaboration in the region.‚Äù said Mats Granryd  Director General  GSMA.About GSMAThe GSMA is a global organisation unifying the mobile ecosystem to discover  develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people  industry  and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries  the GSMA delivers for its members across three broad pillars: Connectivity for Good  Industry Services and Solutions  and Outreach. This activity includes advancing policy  tackling today‚Äôs biggest societal challenges  underpinning the technology and interoperability that make mobile work  and providing the world‚Äôs largest platform to convene the mobile ecosystem at the MWC and M360 series of events.We invite you to find out more at gsma.comAbout Beeline UzbekistanBeeline Uzbekistan is a digital operator that serves 8.2 million customers with mobile connectivity and 7.6 million total monthly active users across its digital services and applications. Its digital portfolio includes financial services application BeePul  digital-first brand OQ  the recently launched streaming application Kinom and super-app Hambi. Beelab and VEON Adtech are also also headquartered in Uzbekistan  contributing to software and IT technologies ecosystem in the country. Beeline Uzbekistan is wholly owned by VEON  a Nasdaq- and Euronext Amsterdam-listed company.About VEONVEON is a digital operator that provides converged connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world‚Äôs population  VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on Nasdaq and Euronext. For more information visit: www.veon.com .DisclaimerThis release contains ‚Äúforward-looking statements ‚Äù as the phrase is defined in Section 27A of the U.S. Securities Act of 1933  as amended  and Section 21E of the U.S. Securities Exchange Act of 1934  as amended. Forward-looking statements are not historical facts  and include statements relating to  among other things  VEON‚Äôs brand partnerships  sponsorships and business outlook. Forward-looking statements are inherently subject to risks and uncertainties  many of which VEON cannot predict with accuracy and some of which VEON might not anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update  except as required by U.S. federal securities laws  any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events.Contact InformationGSMAGSMA Press Officepressoffice@gsma.comVEONHande AsikGroup Director of Communications and Strategypr@veon.comAttachment",neutral,0.0,1.0,0.0,mixed,0.58,0.12,0.29,True,English,"['M360 Eurasia', 'Digital Technologies', 'Beeline Uzbekistan', 'GSMA', 'Tashkent', 'partnership', 'Ministry', 'U.S. federal securities laws', 'U.S. Securities Exchange Act', '7.6 million total monthly active users', 'U.S. Securities Act', 'ambitious digitalization agenda', 'significant regional platforms', 'South Asian markets', 'three broad pillars', 'positive business environments', 'biggest societal challenges', 'financial services application', 'IT technologies ecosystem', 'sustainable economic growth', 'regional mobile ecosystem', 'Euronext Amsterdam-listed company', 'Beeline Uzbekistan Chairman', 'subsidiary Beeline Uzbekistan', 'global digital operator', 'VEON Group CEO', '8.2 million customers', '160 million customers', 'business outlook', 'streaming application', 'societal change', 'global organisation', 'Digital Technologies', 'digital services', 'technology-driven services', 'digital transformation', 'digital inclusion', 'digital portfolio', '20-21 May', 'signing ceremony', 'host sponsor', 'Sherzod Shermatov', 'dynamic Central', 'Kaan Terzioglu', 'first time', 'important milestone', 'Central Asia', 'new ways', 'Mats Granryd', 'Director General', 'mobile operators', 'adjacent industries', 'digital-first brand', 'six countries', 'Section 27A', 'Section 21E', 'historical facts', 'other things', 'brand partnerships', 'forward-looking statement', 'Industry Services', 'M360 Eurasia', 'M360 MENA', 'global events', 'mobile industry', 'mobile connectivity', 'full power', 'largest platform', 'converged connectivity', 'important event', 'M360 series', 'VEON Ltd.', 'VEON Adtech', 'The GSMA', 'statements', 'GSMA.', 'Dubai', 'Tashkent', 'Nasdaq', 'Memorandum', 'Understanding', 'MoU', 'Ministry', 'Republic', 'place', 'Doha', 'Qatar', 'innovation', 'foundation', 'city', 'crossroads', 'prosperity', 'country', 'role', 'capital', 'Minister', 'privilege', 'headquarters', 'commitment', 'thanks', 'support', 'collaboration', 'vision', 'people', 'society', 'organisations', 'members', 'Good', 'Solutions', 'Outreach', 'activity', 'advancing', 'policy', 'interoperability', 'world', 'MWC', 'applications', 'BeePul', 'OQ', 'Kinom', 'super-app', 'Hambi', 'Beelab', 'software', 'population', 'lives', 'individuals', 'information', 'Disclaimer', 'release', 'phrase', 'sponsorships', 'risks', 'uncertainties', 'accuracy', 'date', 'circumstances', 'occurrence']",2024-11-19,2024-11-20,globenewswire.com
47091,EuroNext,NewsApi.org,https://financialpost.com/globe-newswire/invitation-to-attend-the-special-shareholders-meeting-of-the-company-to-be-held-on-december-19-2024,Invitation to attend the special shareholders‚Äô meeting of the Company to be held on December 19  2024,REGULATED INFORMATIONNovember 19  2024  7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12  1435 Mont-Saint-Guibert  Belgium(hereinafter the ‚ÄúCompany‚Äù) Invitation to attend the special shareholders‚Äô meeting of the Company to‚Ä¶,REGULATED INFORMATIONNovember 19  2024  7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12  1435 Mont-Saint-Guibert  Belgium(hereinafter the ‚ÄúCompany‚Äù) Invitation to attend the special shareholders‚Äô meeting of the Company to‚Ä¶,neutral,0.02,0.97,0.0,neutral,0.0,1.0,0.0,True,English,"['special shareholders‚Äô meeting', 'Invitation', 'Company', 'December', '2024', 'Rue Edouard Belin', 'special shareholders‚Äô meeting', 'REGULATED INFORMATIONNovember', 'NYXOAH SA', 'Euronext Brussels/Nasdaq', '7:00am CET', '1:00am', 'NYXH', '1435 Mont-Saint-Guibert', 'Belgium', 'Company', 'Invitation']",2024-11-19,2024-11-20,financialpost.com
47092,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983879/0/en/Solutions30-successfully-completes-120-million-debt-refinancing.html,Solutions30 successfully completes ‚Ç¨120 million debt refinancing,Solutions30  a European leader in rapid-response field services for the telecommunications  energy and IT sectors  today announces that it has successfully closed a ‚Ç¨120 million credit facility. This new facility  arranged with a syndicate of eight core relat‚Ä¶,"Solutions30  a European leader in rapid-response field services for the telecommunications  energy and IT sectors  today announces that it has successfully closed a ‚Ç¨120 million credit facility. This new facility  arranged with a syndicate of eight core relationship banks  will refinance the Group‚Äôs existing bank debt and provide additional financial means for its continued expansion  notably in the Energy sector.Amaury Boilot  Group General Secretary  commented: ""In today‚Äôs challenging financing environment  securing the full refinancing of our bank debt under favorable economic conditions is a testament to the strength of our business model  the quality of our credit profile  and the confidence our lenders have in the Group‚Äôs long-term growth potential. This refinancing strengthens our financial foundation and provides the resources needed to support our continued expansion  both organically and through bolt-on acquisitions  while remaining aligned with our non-dilutive financing policy.""The new ‚Ç¨120 million credit facility  maturing in 2031  extends the Group‚Äôs debt maturity profile. Its cost is tied to the 3-month Euribor  with spreads close to those of the existing debt facility.This refinancing was structured by two leading French banks  BGL BNP Paribas and Soci√©t√© G√©n√©rale  and has been finalized as of today.Upcoming eventsCIC Forum (Virtual Day) - November 21  20242024 Q4 Revenue - January 29  2025About Solutions30 SESolutions30 provides consumers and businesses with access to the key technological advancements that are shaping our everyday lives  especially those driving the digital transformation and energy transition. With its network of more than 16 000 technicians  Solutions30 has completed over 65 million call-outs since its inception and led over 500 renewable energy projects with a combined maximum output surpassing 1600 MWp. Every day  Solutions30 is doing its part to build a more connected and sustainable world. Solutions30 has become an industry leader in Europe with operations in 10 countries: France  Italy  Germany  the Netherlands  Belgium  Luxembourg  Spain  Portugal  the United Kingdom  and Poland.The capital of Solutions30 SE consists of 107 127 984 shares  equal to the number of theoretical votes that can be exercised. Solutions30 SE is listed on the Euronext Paris exchange (ISIN FR0013379484- code S30).Indices: CAC Mid & Small | CAC Small | CAC Technology | Euro Stoxx Total Market Technology | Euronext Tech Growth.Visit our website for more information: www.solutions30.com.ContactIndividual Shareholders:shareholders@solutions30.com - Tel: +33 (0)1 86 86 00 63Analysts/investors:investor.relations@solutions30.comPress - Image 7:Charlotte Le Barbier - Tel: +33 6 78 37 27 60 - clebarbier@image7.frAttachment",neutral,0.12,0.87,0.01,negative,0.0,0.36,0.64,True,English,"['‚Ç¨120 million debt refinancing', 'Solutions30', 'Soci√©t√© G√©n√©rale', 'Euro Stoxx Total Market Technology', 'eight core relationship banks', 'two leading French banks', 'new ‚Ç¨120 million credit facility', 'rapid-response field services', 'challenging financing environment', 'favorable economic conditions', 'long-term growth potential', 'dilutive financing policy', 'BGL BNP Paribas', 'key technological advancements', 'Euronext Paris exchange', 'Euronext Tech Growth', 'Charlotte Le Barbier', 'existing debt facility', 'additional financial means', 'existing bank debt', 'debt maturity profile', '500 renewable energy projects', 'Group General Secretary', 'new facility', 'credit profile', 'CAC Technology', '65 million call-outs', 'financial foundation', 'European leader', 'IT sectors', 'continued expansion', 'Energy sector', 'Amaury Boilot', 'business model', '3-month Euribor', 'Upcoming events', 'CIC Forum', 'Virtual Day', '2024 Q4 Revenue', 'everyday lives', 'digital transformation', 'energy transition', 'maximum output', 'sustainable world', 'industry leader', 'United Kingdom', 'theoretical votes', 'FR0013379484- code', 'CAC Small', 'Individual Shareholders', 'full refinancing', 'Solutions30 SE', 'telecommunications', 'syndicate', 'today', 'testament', 'strength', 'quality', 'confidence', 'lenders', 'resources', 'bolt', 'acquisitions', 'non', 'cost', 'spreads', 'November', 'January', 'consumers', 'businesses', 'access', 'network', '16,000 technicians', 'inception', '1600 MWp', 'part', 'connected', 'operations', '10 countries', 'France', 'Italy', 'Germany', 'Netherlands', 'Belgium', 'Luxembourg', 'Spain', 'Portugal', 'Poland', 'capital', '107,127,984 shares', 'number', 'Indices', 'website', 'information', 'Contact', 'investors', 'Press', 'Image', 'clebarbier', 'Attachment']",2024-11-19,2024-11-20,globenewswire.com
47093,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983262/0/en/Dapirolizumab-Pegol-Phase-3-Data-Presented-at-the-American-College-of-Rheumatology-Shows-Significant-Reduction-in-Systemic-Lupus-Erythematosus-Disease-Activity.html,Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity,BRUSSELS  Belgium and CAMBRIDGE  Mass.  Nov. 19  2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP)  a novel Fc-free ant‚Ä¶,Dapirolizumab pegol (DZP) met its primary endpoint  demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA  an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic  debilitating autoimmune disease affecting multiple organ systems  primarily in women  for whom there is a significant need for additional treatment optionsBRUSSELS  Belgium and CAMBRIDGE  Mass.  Nov. 19  2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP)  a novel Fc-free anti-CD40L drug candidate  demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). The results were shared during an oral  late-breaker presentation at ACR Convergence 2024  the American College of Rheumatology‚Äôs annual meeting  in Washington  DC.‚ÄúThere remains a significant unmet need for additional treatment options for people living with systemic lupus erythematosus and the results we observed in PHOENYCS GO suggest dapirolizumab pegol has the potential to be impactful for this chronic and debilitating autoimmune disease. Across clinical endpoints we observed a positive effect and a favorable safety profile ‚Äù said Megan E.B. Clowse  M.D.  principal investigator of the study and Associate Professor of Medicine  Chief of the Division of Rheumatology and Immunology at Duke University School of Medicine. ‚ÄúParticipants receiving dapirolizumab pegol experienced reduced lupus activity while also tapering steroids  changes important to people living with the disease.‚ÄùIn the PHOENYCS GO study (n=321)  dapirolizumab pegol (DZP) was administered intravenously every four weeks. On the primary endpoint measuring improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks  study participants receiving DZP plus SOC had a statistically significant 14.6% (95% confidence interval [CI]: 3.3  25.8; p=0.0110) higher response rate (49.5%) than those receiving SOC alone (34.6%). A higher BICLA response rate reflects a treatment response across all affected organs at baseline and is associated with meaningful clinical benefit.On the first secondary endpoint of BICLA response at Week 24  study participants receiving DZP plus SOC had a 7.9% higher response rate (46.6%) than those receiving SOC alone (38.3%). However  the difference did not reach statistical significance (95% CI: -3.6  19.4; p=0.1776). Given statistical significance was not achieved for the first key secondary endpoint in the hierarchical testing  analyses for all the subsequent secondary endpoints are descriptive and nominal p-values are included.Subsequent analyses of additional secondary endpoints showed clinical improvements in the DZP group  including SLE Responder Index (SRI)-4 response  corticosteroid tapering  SLE Disease Activity Index-2K (SLEDAI-2K)  achievement of Lupus Low Disease Activity State (LLDAS) and prevention of severe BILAG flares:17.1% more participants receiving DZP were able to reduce their corticosteroid dose from >7.5 mg/day prednisone equivalent at baseline to ‚â§7.5 mg/day at Week 48 (72.4% vs. 52.9%; difference [95% CI]: 17.1% [0.7  33.4]; nominal p=0.0404).18.8% higher SRI-4 response rate at Week 48 (95% CI: 7.3  30.3; nominal p=0.0014) among study participants who received DZP plus SOC (60.1%) versus those who received SOC alone (41.1%).A 1.8-fold greater decrease from baseline in SLEDAI-2K in study participants receiving DZP plus SOC compared to SOC alone at Week 48 (-6.1 vs ‚Äì4.2; difference [95% CI]: -1.8 [-2.7  -0.9]; nominal p=0.0001).A 20.9% greater proportion of participants in the DZP group achieved LLDAS at Week 48 compared to SOC alone (40.9% vs. 19.6%; difference [95% CI]: 20.9% [10.7 31.2]; nominal p<0.001).Participants receiving DZP plus SOC had 50% fewer severe BILAG flares through Week 48 (95% CI: 1.4  21.6; nominal p=0.0257) compared to SOC alone (11.6% vs. 23.4%).‚ÄúDue to the varied symptoms and severity by patient  progress in the treatment of lupus has historically been challenging. With dapirolizumab pegol  we believe that our differentiated approach that targets the CD40L pathway results in clinically meaningful improvements across multiple disease domains and could substantially impact the burden of this disease in particular for women  who are disproportionately affected by lupus ‚Äù said Fiona du Monceau  Head of Patient Evidence at UCB. ‚ÄúWe are highly encouraged by the results we have seen in PHOENYCS GO and are excited to continue the clinical development of dapirolizumab pegol in the second Phase 3 study  PHOENYCS FLY.‚ÄùThe safety profile of dapirolizumab pegol was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. In the PHOENYCS GO study  a higher proportion of patients receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs. 75.0%). The proportion of participants with serious TEAEs was 9.9% in those participants receiving DZP plus SOC compared to 14.8% in those receiving SOC alone. Opportunistic infections were reported in 2.8% of participants receiving DZP plus SOC compared to 0.9% of those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone.‚ÄúAt Biogen  we understand that lupus affects everyone differently and are committed to developing treatments as diverse as the patients we serve ‚Äù said Diana Gallagher  MD  Head of AD  MS and Immunology Development Units at Biogen. ‚ÄúThese results reinforce our belief that dapirolizumab pegol has the potential to change the approach to care of SLE and we are dedicated to advancing this program with our partner UCB.‚ÄùParticipants from the PHOENYCS GO study will continue to be followed in a long-term open-label study. In 2024  UCB and Biogen will initiate a second Phase 3 trial of dapirolizumab pegol  PHOENYCS FLY (NCT06617325).The safety and efficacy of dapirolizumab pegol in systemic lupus erythematosus have not been established  and it is not approved for use in systemic lupus erythematosus by any regulatory authority worldwide.About Systemic Lupus Erythematosus (SLE)SLE is a chronic  multifactorial autoimmune disease that is caused by the activation of autoreactive T  B and antigen-presenting cells  resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.1 SLE can present itself in several ways including rash  arthritis  anemia  thrombocytopenia  serositis  nephritis  seizures or psychosis.2 SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease.An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.3 4 5 Individuals from populations of African  Hispanic  Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.6 7 Pregnancy in women with SLE is high risk  with higher maternal and fetal mortality and morbidity than the general population.8 9About Dapirolizumab PegolDapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab‚Äô) fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production  mitigate type 1 interferon (IFN) secretion  and attenuate T cell and antigen-presenting cell (APC) activation.10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.11About UCBUCB  Brussels  Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB is listed on Euronext Brussels (symbol: UCB).About BiogenFounded in 1978  Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient‚Äôs lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks  balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow us on social media - Facebook  LinkedIn  X  YouTube.Forward looking statements UCBThis press release may contain forward-looking statements including  without limitation  statements containing the words ‚Äúbelieves‚Äù  ‚Äúanticipates‚Äù  ‚Äúexpects‚Äù  ‚Äúintends‚Äù  ‚Äúplans‚Äù  ‚Äúseeks‚Äù  ‚Äúestimates‚Äù  ‚Äúmay‚Äù  ‚Äúwill‚Äù  ‚Äúcontinue‚Äù and similar expressions. These forward-looking statements are based on current plans  estimates and beliefs of management. All statements  other than statements of historical facts  are statements that could be deemed forward-looking statements  including estimates of revenues  operating margins  capital expenditures  cash  other financial information  expected legal  arbitration  political  regulatory or clinical results or practices and other such estimates and results. By their nature  such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks  uncertainties and assumptions which might cause the actual results  financial condition  performance or achievements of UCB  or industry results  to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic  business and competitive conditions  the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing  costs associated with research and development  changes in the prospects for products in the pipeline or under development by UCB  effects of future judicial decisions or governmental investigations  safety  quality  data integrity or manufacturing issues; potential or actual data security and data privacy breaches  or disruptions of our information technology systems  product liability claims  challenges to patent protection for products or product candidates  competition from other products including biosimilars  changes in laws or regulations  exchange rate fluctuations  changes or uncertainties in tax laws or the administration of such laws  and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline  will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far  the complexity of the human body cannot be reproduced in computer models  cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products  which are the subject of partnerships  joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe  effective or commercially successful as UCB may have believed at the start of such partnership. UCB‚Äôs efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also  UCB or others could discover safety  side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB‚Äôs products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover  sales may be impacted by international and domestic trends toward managed care and health care cost containment  including pricing pressure  political and public scrutiny  customer and prescriber patterns or practices  and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally  a breakdown  cyberattack or information security breach could compromise the confidentiality  integrity and availability of UCB‚Äôs data and systems.Given these uncertainties  you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market  or at any particular time  nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.UCB is providing this information  including forward-looking statements  only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release  either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events  conditions or circumstances on which any such statement is based  unless such statement is required pursuant to applicable laws and regulations.Additionally  information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities  nor shall there be any offer  solicitation or sale of securities in any jurisdiction in which such offer  solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.Biogen Safe HarborThis news release contains forward-looking statements  including but not limited to those relating to the potential benefits  safety and efficacy of DZP; the timing and status of current and future regulatory filings; risks and uncertainties associated with drug development and commercialization; the potential of Biogen‚Äôs commercial business and pipeline programs; the anticipated benefits and potential of Biogen‚Äôs collaboration arrangements with UCB; Biogen‚Äôs strategy and plans; and potential cost healthcare savings related to biosimilars. These forward-looking statements may be accompanied by words such as ‚Äúaim ‚Äù ‚Äúanticipate ‚Äù ‚Äúbelieve ‚Äù ‚Äúcould ‚Äù ‚Äúestimate ‚Äù ‚Äúexpect ‚Äù ‚Äúforecast ‚Äù ‚Äúintend ‚Äù ‚Äúmay ‚Äù ‚Äúplan ‚Äù ‚Äúpotential ‚Äù ‚Äúpossible ‚Äù ‚Äúwill ‚Äù ‚Äúwould‚Äù and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk  and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements  including without limitation  actual timing and content of submissions to and decisions made by the regulatory authorities regarding DZP; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies  or may fail or refuse to approve or may delay approval of DZP; risks of unexpected costs or delays or other unexpected hurdles; uncertainty of success in the development and potential commercialization of DZP  which may be impacted by  among other things  the level of preparedness of healthcare providers to treat patients  difficulties in obtaining or changes in the availability of reimbursement for DZP and other unexpected difficulties or hurdles; the occurrence of adverse safety events; unexpected concerns that may arise from additional data or analysis; failure to protect and enforce data  intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; risks of legal actions  regulatory scrutiny or other challenges to biosimilars  results of operations and financial condition; product liability claims; and third party collaboration risks. The foregoing sets forth many  but not all  of the factors that could cause actual results to differ from Biogen‚Äôs expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen‚Äôs most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen‚Äôs current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.References:Tselios K  Gladman DD  Touma Z  et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. Fanouriakis A  Tziolos N  Bertsias G  et al. Update Œøn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272 Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. Epub 2002/12/11. doi: 10.1053/berh.2002.0259. PubMed PMID: 12473278. Rees F  Doherty M  Grainge M  Davenport G  Lanyon P  Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK  1999-2012. Ann Rheum Dis. 2016;75(1):136-41. Epub 2014/10/01. doi: 10.1136/annrheumdis-2014-206334. PubMed PMID: 25265938; PubMed Central PMCID: PMCPMC4717400. Pons-Estel GJ  Ugarte-Gil MF  Alarc√≥n GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799-814. Carter EE  Barr SG  Clarke AE. The global burden of SLE: prevalence  health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. Epub 2016/08/26. doi: 10.1038/nrrheum.2016.137. PubMed PMID: 27558659. Kheir JM  Guthridge CJ  Johnston JR  Adams LJ  Rasmussen A  Gross TF  et al. Unique clinical characteristics  autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PubMed Central PMCID: PMCPMC5844376. Mehta B  Luo Y  Xu J  Sammaritano L  Salmon J  Lockshin M  et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164-71. Epub 2019/07/10. doi: 10.7326/M19-0120. PubMed PMID: 31284305. Bitencourt N  Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception  Pregnancy and Breastfeeding. Paediatr Drugs. Furie RA  Bruce IN  D√∂rner T  et al. Phase 2 randomized  placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford).2021;60(11): 5397-407. Clinicaltrials.gov (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023 [cited August 2024] Available at: https://clinicaltrials.gov/ct2/showithNCT04294667. Retrieved July 25  2024.,neutral,0.0,0.99,0.01,mixed,0.2,0.2,0.6,True,English,"['Systemic Lupus Erythematosus Disease Activity', 'Dapirolizumab Pegol Phase 3 Data', 'American College', 'Significant Reduction', 'Rheumatology', 'novel Fc-free anti-CD40L drug candidate', 'BILAG)-based Composite Lupus Assessment', 'British Isles Lupus Assessment Group', 'Lupus Low Disease Activity State', 'Megan E.B. Clowse', '8% higher SRI-4 response rate', '50% less severe disease flares', 'moderate-to-severe systemic lupus erythematosus', 'first key secondary endpoint', 'chronic, debilitating autoimmune disease', 'SLE Disease Activity Index', 'higher BICLA response rate', 'Phase 3 PHOENYCS GO study', 'severe BILAG flares', 'higher response rate', 'moderate-to-severe disease activity', 'SLE Responder Index', 'first secondary endpoint', 'oral, late-breaker presentation', 'Duke University School', 'additional secondary endpoints', 'day prednisone equivalent', 'Fiona du Monceau', 'multiple disease domains', 'second Phase 3 study', 'subsequent secondary endpoints', '1.8-fold greater decrease', 'multiple clinical endpoints', 'additional treatment options', 'multiple organ systems', 'significant unmet need', 'favorable safety profile', 'meaningful clinical benefit', 'significant clinical improvement', 'lupus activity', 'greater response', 'significant need', 'treatment response', 'SRI)-4 response', 'PHOENYCS FLY', 'significant improvement', 'clinical improvements', 'meaningful improvements', 'clinical development', 'primary endpoint', '20.9% greater proportion', 'DZP group', 'Dapirolizumab pegol', 'GLOBE NEWSWIRE', 'Biogen Inc.', 'ACR Convergence', 'American College', 'annual meeting', 'positive effect', 'M.D.', 'principal investigator', 'Associate Professor', 'statistical significance', 'hierarchical testing', 'nominal p-values', 'Subsequent analyses', 'corticosteroid tapering', 'corticosteroid dose', 'varied symptoms', 'differentiated approach', 'CD40L pathway', 'study participants', 'Euronext Brussels', 'Patient Evidence', 'detailed results', 'standard', 'care', 'women', 'Belgium', 'CAMBRIDGE', 'Mass.', 'UCB', 'NASDAQ', 'BIIB', 'people', 'Rheumatology', 'Washington', 'DC', 'potential', 'Medicine', 'Chief', 'Division', 'Immunology', 'steroids', 'achievement', '48 weeks', 'organs', 'baseline', 'difference', 'SLEDAI', 'LLDAS', 'prevention', '>7.5 mg', '‚â§7.5 mg', '50% fewer', 'severity', 'progress', 'burden', 'Head', '52', '23.']",2024-11-19,2024-11-20,globenewswire.com
47094,EuroNext,NewsApi.org,https://www.investing.com/news/press-releases/innate-pharma-announces-publication-in-science-immunology-highlighting-innovative-nextgeneration-anket--iph6501-93CH-3729325,Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ¬Æ IPH6501 By Investing.com,Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ¬Æ IPH6501,"IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2  targeting CD20 and developed for B-NHLIPH6501 boosts NK cell proliferation and cytotoxicity  showing activity in vitro against a range of B-NHL cell lines  in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patientsIn vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumorsResults support clinical development of IPH6501 in R/R B-NHLMARSEILLE  France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (OTC: ) ( Euronext (EPA: ) Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501  Innate's proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET ¬Æ platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654).The data published shows that IPH6501  also called CD20-NKCE-IL2v in the publication  boosts NK cell proliferation and cytotoxicity  showing activity against a range of B-NHL cell lines  including those with low CD20 density. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that IPH6501 induces peripheral NK cell migration at the tumor site.These new findings underscore the remarkable potential of IPH6501 to transform the treatment landscape for B-NHL. IPH6501 showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models while presenting reduced toxicities compared with those commonly associated with T cell therapies. We are particularly encouraged by results that reveal IPH6501's ability to drive NK cell migration directly to tumor sites  highlighting its potential as a game-changer in immuno-oncology. These findings are a testament to the promise of NK cell therapies to deliver safer and more targeted solutions for patients in need  commented Eric Vivier  DVM  PhD  Chief Scientific Officer of Innate Pharma (EPA: ).The data published further support the current clinical development plan of IPH6501 in Relapsed/Refractory B-NHL.About ANKET ¬ÆANKET ¬Æ (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation  multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile  fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.About IPH6501IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16)  IL-2R (but not a subunit) through a variant of human IL-2  and a tumor antigen (CD20) via a single molecule  hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria  EHA 2023  Carrette  SITC 2024  Demaria et al  Science Immunology 2024).IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654)  investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma.About Innate PharmaInnate Pharma S.A. is a global  clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies  multi-specific NK Cell Engagers via its ANKET ¬Æ (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).Innate's portfolio includes lead proprietary program lacutamab  developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas  monalizumab developed with AstraZeneca (NASDAQ: ) in non-small cell lung cancer  several ANKET ¬Æ drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi (NASDAQ: ) and AstraZeneca  as well as leading research institutions  to accelerate innovation  research and development for the benefit of patients.Headquartered in Marseille  France with a US office in Rockville  MD  Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.Information about Innate Pharma sharesISIN codeTicker codeLEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29Disclaimer on forward-looking information and risk factorsThis press release contains certain forward-looking statements  including those within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. The use of certain words  including anticipate  believe  can  could  estimate  expect  may  might  potential  expect should  will  or the negative of these and similar expressions  is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those anticipated. These risks and uncertainties include  among other things  the uncertainties inherent in research and development  including related to safety  progression of and results from its ongoing and planned clinical trials and preclinical studies  review and approvals by regulatory authorities of its product candidates  the Company's reliance on third parties to manufacture its product candidates  the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties  which could cause the Company's actual results  financial condition  performance or achievements to differ from those contained in the forward-looking statements  please refer to the Risk Factors (Facteurs de Risque"") section of the Universal Registration Document filed with the French Financial Markets Authority (AMF)  which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website  www.innate-pharma.com  and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC)  including the Company's Annual Report on Form 20-F for the year ended December 31  2023  and subsequent filings and reports filed with the AMF or SEC  or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein  or that can be accessed through them  are not incorporated by reference into  and do not constitute a part of  this press release.In light of the significant uncertainties in these forward-looking statements  you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements  whether as a result of new information  future events or otherwise  except as required by law.This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.View source version on businesswire.com: https://www.businesswire.com/news/home/20241118258203/en/For additional information  please contact:InvestorsInnate PharmaHenry WheelerTel.: +33 (0)4 84 90 32 88Henry.wheeler@innate-pharma.frMedia RelationsNewCapArthur Rouill√É¬©Tel.: +33 (0)1 44 71 00 15innate@newcap.euSource: Innate Pharma SA",neutral,0.0,1.0,0.0,mixed,0.23,0.25,0.52,True,English,"['Innovative Next-generation ANKET', 'Innate Pharma', 'Science Immunology', 'Publication', 'Investing', 'first Antibody-based NK cell Engager Therapeutic', 'monoclonal antibodies, multi-specific NK Cell Engagers', 'Private Securities Litigation Reform Act', 'Antibody-based NK cell Engager Therapeutics', 'next-generation, multi-specific natural killer', 'Phase 1/2 multicenter trial', 'cutaneous T cell lymphomas', 'Phase 1/2 clinical trial', 'proprietary NK cell engager', 'peripheral T cell lymphomas', 'lead proprietary program lacutamab', 'peripheral NK cell migration', 'class tetra-specific NK cell', 'global, clinical-stage biotechnology company', 'Refractory CD20-expressing B-cell Non-Hodgkin', 'small cell lung cancer', 'current clinical development plan', 'several ANKET ¬Æ drug candidates', 'Innate Pharma S.A.', 'NK) cell engagers', 'T cell engager', 'NK cell therapies', 'three therapeutic approaches', 'T cell therapies', 'applicable securities laws', 'NK cell proliferation', 'peripheral NK cells', 'Antibody Drug Conjugates', 'B-cell non-Hodgkin lymphoma', 'Chief Scientific Officer', 'B-NHL cell lines', 'various preclinical models', 'tumor mouse models', 'preclinical tumor models', 'greater killing efficacy', 'innate immune system', 'leading research institutions', 'vitro preclinical models', 'low CD20 density', 'multiple tumor types', 'Innate Pharma SA', 'Innate Pharma shares', 'R/R B-NHL patients', 'benchmark antibodies', 'Refractory B-NHL', 'proprietary platform', 'new class', 'tumor site', 'tumor antigen', 'malignant cells', 'preclinical data', 'vivo studies', 'BUSINESS WIRE', 'Regulatory News', 'Science Immunology', 'nonhuman primates', 'treatment landscape', 'reduced toxicities', 'targeted solutions', 'Eric Vivier', 'purpose technology', 'synthetic immunity', 'single molecule', 'activation signals', 'anti-tumor efficacy', 'innovative approach', 'advanced form', 'trusted partner', 'biopharmaceutical companies', 'ISIN code', 'Ticker code', 'risk factors', 'press release', 'forward-looking statements', 'ANKET ¬Æ platform', 'CD20 expressing', 'cancer patients', 'new findings', 'human IL-2', 'differentiated ADC', 'solid tumors', 'US office', 'IPHA 9695002Y8420ZB8HJE29', 'looking information', 'remarkable potential', 'cytotoxic activity', 'Euronext Paris', 'IPH Nasdaq', 'B-NHL.', 'IPH6501', 'variant', 'cytotoxicity', 'range', 'samples', 'ability', 'Results', 'MARSEILLE', 'France', 'OTC', 'EPA', 'publication', 'IL-2v', 'game-changer', 'immuno-oncology', 'testament', 'promise', 'safer', 'need', 'DVM', 'PhD', 'molecules', 'receptors', 'NKp46', 'IL-2R', 'subunit', 'Demaria', 'EHA', 'Carrette', 'SITC', 'NCT06088654', 'safety', 'Relapsed', 'immunotherapies', 'portfolio', 'monalizumab', 'AstraZeneca', 'IPH4502', 'Sanofi', 'innovation', 'benefit', 'Rockville', 'MD', 'LinkedIn', 'LEI', 'Disclaimer', 'meaning', 'words']",2024-11-19,2024-11-20,investing.com
47095,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983267/0/en/Nicox-Announces-Publication-of-the-Adaptive-Design-Period-of-the-NCX-470-Mont-Blanc-Phase-3-Trial.html,Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial,Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase¬†3 Trial  An adaptive design is a useful...,Press ReleaseNicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 TrialAn adaptive design is a useful clinical trial design tool which allowed identification of the optimal dose of NCX 470 in the Mont Blanc trial  the first Phase 3 trial of NCX 470Both doses of NCX 470 ophthalmic solution tested  0.065% and 0.1%  lowered intraocular pressure more than the comparator  latanoprost 0.005% ophthalmic solutionThe 0.1% NCX 470 concentration was chosen for the remainder of the Mont Blanc trial and the ongoing Denali trial based on a greater intraocular pressure reduction compared to the 0.065% concentration and a good safety profile November 18  2024 ‚Äì release at 7:30 am CETSophia Antipolis  FranceNicox SA (Euronext Growth Paris: FR0013018124  ALCOX)  an international ophthalmology company  today announced that the design details and results of the adaptive design period of the NCX 470 Mont Blanc Phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online in Contemporary Clinical Trials  Volume 147  2024  107730 (online pre-publication https://doi.org/10.1016/j.cct.2024.107730). A portion of this data has previously been presented as a poster at the 2023 World Glaucoma Congress.The dose finding Phase 2 trial (Dolomites) tested NCX 470 at several concentrations and the results suggested that a higher dose than those tested might provide even better efficacy and safety profile. To test this  concentrations of 0.065% and 0.1% were included in an adaptive dose selection period of the Phase 3 Mont Blanc trial  which compared the safety and efficacy of NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution in adult subjects with open-angle glaucoma or ocular hypertension. At the Week 2 timepoint  the least-squares mean difference in diurnal intraocular pressure (IOP) compared to latanoprost were 1.51 mmHg for NCX 470 0.065 % group (p = 0.0308) and 1.71 mmHg for NCX 470 0.1 % group (p = 0.0123)  in favor of NCX 470. The most common side effect was conjunctival/ocular hyperemia  the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05).The adaptive dose selection period was used in place of additional dose ranging studies to select the 0.1% concentration of NCX 470 for the completion of the Mont Blanc clinical trial as well as the second Phase 3 trial  Denali.The results of the Mont Blanc trial were announced in October 2022. The second Phase 3 trial of NCX 470  Denali  is ongoing and topline results are expected in the third quarter of 2025.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox‚Äôs lead program in clinical development is NCX 470 (bimatoprost grenod)  a novel nitric oxide-donating bimatoprost eye drop  for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728  a nitric oxide-donating phosphodiesterase-5 inhibitor  with Glaukos. Nicox‚Äôs first product  VYZULTA¬Æ in glaucoma  licensed exclusively worldwide to Bausch + Lomb  is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE¬Æ in allergic conjunctivitis  licensed in multiple geographies  including to Harrow  Inc. in the U.S.  and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox  headquartered in Sophia Antipolis  France  is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York  U.S.The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally  the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.comDisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates  directors  officers  employees  advisers or agents  do not undertake  nor do they have any obligation  to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox‚Äôs business are presented in section 3 of the ‚ÄúRapport Annuel 2023‚Äù and in section 4 of the ‚ÄúRapport semestriel financier et d‚Äôactivit√© 2024‚Äù which are available on Nicox‚Äôs website (www.nicox.com).Finally  this press release may be drafted in the French and English languages. If both versions are interpreted differently  the French language version shall prevail.,neutral,0.0,1.0,0.0,mixed,0.17,0.24,0.6,True,English,"['NCX 470 Mont Blanc Phase 3 Trial', 'Adaptive Design Period', 'Nicox', 'Publication', 'novel nitric oxide-donating bimatoprost eye drop', 'Co Yi Chen New York', 'useful clinical trial design tool', 'nitric oxide-donating phosphodiesterase-5 inhibitor', 'NCX 470 Mont Blanc Phase 3 Trial', 'additional dose ranging studies', 'Phase 3 Mont Blanc trial', 'Mont Blanc clinical trial', 'adaptive dose selection period', 'greater intraocular pressure reduction', 'second Phase 3 trial', 'Adaptive Design Period', 'first Phase 3 trial', 'Contemporary Clinical Trials', 'Euronext Growth Paris', 'international ophthalmology company', 'squares mean difference', 'Southeast Asian markets', 'CAC Healthcare index', 'H.C. Wainwright', 'Chief Executive Officer', 'diurnal intraocular pressure', 'common side effect', 'preclinical research program', 'Rapport semestriel financier', 'ongoing Denali trial', '2023 World Glaucoma Congress', 'NCX 470 dosing groups', 'NCX 470 ophthalmic solution', 'Such forward-looking statements', 'good safety profile', 'latanoprost ophthalmic solution', 'Phase 2 trial', 'Nicox S.A.', 'bimatoprost grenod', '0.005% ophthalmic solution', 'clinical development', 'design details', 'optimal dose', 'higher dose', 'lead program', 'first product', 'material effect', 'Rapport Annuel', 'U.S.', 'Sophia Antipolis', 'open-angle glaucoma', 'ocular hypertension', 'doi.org', 'adult subjects', 'Week 2 timepoint', 'NCX 470 0.065 % group', 'NCX 470 0.1 % group', 'conjunctival/ocular hyperemia', 'third quarter', 'innovative solutions', 'ocular health', '15 other territories', 'allergic conjunctivitis', 'multiple geographies', 'Ocumension Therapeutics', 'Ticker symbol', 'Gavin Spencer', 'prior notice', 'future performance', 'current expectations', 'Press Release', 'several concentrations', 'Analyst coverage', 'analyst reports', 'Risks factors', 'topline results', 'actual results', '0.1% NCX 470 concentration', 'Nicox SA', '0.065% concentration', '0.1% concentration', 'Publication', 'identification', 'doses', 'comparator', 'remainder', 'France', 'ALCOX', 'efficacy', 'patients', 'Volume', 'portion', 'data', 'poster', 'Dolomites', 'IOP', '1.51 mmHg', '1.71 mmHg', 'favor', 'frequency', 'severity', 'place', 'completion', 'October', 'vision', 'Glaukos', 'VYZULTA¬Æ', 'Bausch', 'Lomb', 'revenue', 'ZERVIATE¬Æ', 'Harrow', 'Inc.', 'Chinese', 'majority', 'part', 'information', 'views', 'analysts', 'author', 'obligation', 'communications', 'Disclaimer', 'document', 'guarantees', 'beliefs', 'management', 'number', 'uncertainties', 'affiliates', 'directors', 'officers', 'employees', 'advisers', 'agents', 'updates', 'business', 'section', 'acti', '7:30']",2024-11-19,2024-11-20,globenewswire.com
47096,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983296/0/en/21Shares-Adds-Staking-to-the-21Shares-Ethereum-Core-ETP-ETHC.html,21Shares Adds Staking to the 21Shares Ethereum Core ETP (ETHC),ZURICH ¬†19 November 2024 ‚Äì 21Shares AG (‚Äú21Shares‚Äù)  one of the world‚Äôs largest issuers of crypto exchange traded products (ETPs)  today announced that the firm has added staking to the 21Sharese Ethereum Core ETP (ETHC) and will be re-naming the product as f‚Ä¶,ZURICH  19 November 2024 ‚Äì 21Shares AG (‚Äú21Shares‚Äù)  one of the world‚Äôs largest issuers of crypto exchange traded products (ETPs)  today announced that the firm has added staking to the 21Sharese Ethereum Core ETP (ETHC) and will be re-naming the product as follows  effective today:Ticker ISIN Current Product Name New Product Name ETHC CH1209763130 21Shares Ethereum Core ETP 21Shares Ethereum Core Staking ETPStaking involves locking specific crypto-assets to support the operation and security of a blockchain network  earning rewards in the process. By integrating staking rewards into 21Shares ETPs  investors enjoy a potential additional income stream without having to keep their assets locked  enhancing overall returns while maintaining exposure to the respective underlying assets.According to Coinbase (as of 17 November 2024)  the average staking yield for Ethereum is 2.24%.‚Äú21Shares is continuing to do what it's done since inception ‚Äì pioneer digital assets innovation for European investors ‚Äù said Hany Rashwan  Co-Founder and CEO of 21Shares. ‚ÄúThe addition of staking to ETHC is the firm‚Äôs latest move to provide the European market with the most cutting-edge digital assets products. We are thrilled to make ETHC even more attractive for investors  helping to offset management fees while also offering the potential for additional returns through staking rewards.‚ÄùListed on SIX Swiss Exchange  Deutsche B√∂rse Xetra  Euronext Amsterdam  Euronext Paris  and London Stock Exchange  ETHC is 100% physically backed by Ether (ETH)  the second-largest cryptoasset by market cap  and tracks ETH‚Äôs performance. ETHC investors gain exposure to ETH through the market's most cost-efficient ETP  featuring management fees as low as 0.21%.For more details about the 21Shares Ethereum Core Staking ETP (ETHC)  including the factsheet  please click here .Press ContactAudrey Belloff  Head of Global Communications  audrey.belloff@21.coAbout 21.co / 21Shares21.co is the world‚Äôs leader in providing access to crypto through simple and easy to use products. 21.co is the parent company of 21Shares  one of the world‚Äôs largest issuers of crypto exchange traded products (ETPs) ‚Äì which is powered by Onyx  a proprietary technology platform used to issue and operate cryptocurrency ETPs for 21Shares and third parties. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. 21Shares is registered in Zurich  Switzerland with offices in Zurich  London and New York. For more information  please visit 21Shares.com .DISCLAIMERThis document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares AG in any jurisdiction. Neither this document nor anything contained herein shall form the basis of  or be relied upon in connection with  any offer or commitment whatsoever or for any other purpose in any jurisdiction. Nothing in this document should be considered investment advice.This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States  Canada  Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful.This document does not constitute an offer of securities for sale in or into the United States  Canada  Australia or Japan. The securities of 21Shares AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933  as amended (the ‚ÄúSecurities Act‚Äù)  and may not be offered or sold in the United States absent registration or an applicable exemption from  or in a transaction not subject to  the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States.Within the United Kingdom  this document is only being distributed to and is only directed at: (i) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ‚ÄúOrder‚Äù); or (ii) high net worth entities  and other persons to whom it may lawfully be communicated  falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ‚Äúrelevant persons‚Äù); or (iii) persons who fall within Article 43(2) of the Order  including existing members and creditors of the Company or (iv) any other persons to whom this document can be lawfully distributed in circumstances where section 21(1) of the FSMA does not apply. The securities are only available to  and any invitation  offer or agreement to subscribe  purchase or otherwise acquire such securities will be engaged in only with  relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.Exclusively for potential investors in any EEA Member State that has implemented the Prospectus Regulation (EU) 2017/1129 the Issuer‚Äôs Base Prospectus (EU) is made available on the Issuer‚Äôs website under www.21Shares.com.The approval of the Issuer‚Äôs Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the Issuer‚Äôs Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand.This document constitutes advertisement within the meaning of the Prospectus Regulation (EU) 2017/1129 and the Swiss Financial Services Act (the ‚ÄúFinSA‚Äù) and not a prospectus. The 2023 Base Prospectus of 21Shares AG has been deposited pursuant to article 54(2) FinSA with SIX Exchange Regulation AG in its function as Swiss prospectus review body within the meaning of article 52 FinSA. The 2023 Base Prospectus and the key information document for any products may be obtained at 21Shares AG's website (https://21shares.com/ir/prospectus or https://21shares.com/ir/kids ).###,neutral,0.0,1.0,0.0,mixed,0.19,0.16,0.65,True,English,"['21Shares Ethereum Core ETP', 'ETHC', 'New Product Name ETHC CH1209763130 21Shares Ethereum Core ETP 21Shares Ethereum Core Staking ETP', 'Ticker ISIN Current Product Name', '21Sharese Ethereum Core ETP', 'Deutsche B√∂rse Xetra', 'high net worth entities', 'pioneer digital assets innovation', 'cutting-edge digital assets products', 'potential additional income stream', 'crypto exchange traded products', 'average staking yield', 'New York', 'SIX Swiss Exchange', 'respective underlying assets', 'proprietary technology platform', 'United States Securities Act', 'London Stock Exchange', 'securities regulatory authority', 'Financial Promotion) Order', '21Shares AG', 'Exchange Commission', 'additional returns', '21Shares ETPs', 'ETHC investors', 'Financial Services', 'Markets Act', 'United Kingdom', 'largest issuers', 'specific crypto-assets', 'blockchain network', 'overall returns', 'Hany Rashwan', 'latest move', 'management fees', 'Euronext Amsterdam', 'Euronext Paris', 'largest cryptoasset', 'Press Contact', 'Audrey Belloff', 'Global Communications', 'audrey.belloff', 'third parties', 'Ophelia Snyder', 'other purpose', 'applicable exemption', 'public offering', 'criminal offence', 'existing members', 'European market', 'market cap', 'investment advice', 'US Securities', 'investment professionals', 'other persons', 'relevant persons', 'European investors', 'cryptocurrency ETPs', 'other jurisdiction', 'registration requirements', 'parent company', 'ZURICH', '19 November', 'world', 'firm', 'operation', 'security', 'rewards', 'process', 'exposure', 'Coinbase', '17 November', 'inception', 'Co-Founder', 'CEO', 'performance', 'details', 'factsheet', 'Head', '21.co', 'leader', 'access', 'simple', 'Onyx', 'Switzerland', 'offices', 'information', 'DISCLAIMER', 'document', 'solicitation', 'basis', 'connection', 'commitment', 'distribution', 'Canada', 'Australia', 'Japan', 'release', 'sale', 'materials', 'transaction', 'accuracy', 'adequacy', 'contents', 'presentation', 'contrary', 'Article', 'creditors', 'circumstances', 'section', 'FSMA', 'invitation', 'agreement']",2024-11-19,2024-11-20,globenewswire.com
47097,EuroNext,NewsApi.org,https://www.investing.com/news/press-releases/afyren-awarded-silver-medal-by-ecovadis-with-an-improved-score-93CH-3729328,AFYREN Awarded Silver Medal by ECOVADIS With an Improved Score By Investing.com,AFYREN Awarded Silver Medal by ECOVADIS With an Improved Score,"AFYREN's silver rating confirmed by sustainability ratings leader EcoVadis  with a score improved by 7 pointsAFYREN is in the top 15% of all companies evaluatedCLERMONT-FERRAND  France & LYON  France--(BUSINESS WIRE)--Regulatory News:AFYREN (Paris:ALAFY)  a greentech company that offers manufacturers biobased  low-carbon ingredients produced using unique fermentation technology based on a completely circular model  is awarded a silver medal by EcoVadis  one of the most recognized independent CSR assessment platforms  and outperforms its score of last year.For the second year in a row  AFYREN has been awarded a silver medal by the global rating platform EcoVadis  with a score of 68/100  placing the Company in the top 15% of companies in terms of sustainable development and in the top 8% of its industrial sector.AFYREN's rating improved by 7 points compared to last year  despite a more demanding set of criteria due to a change in category (from Small to Medium-sized company). This recognition testifies to AFYREN's continuous efforts in terms of Corporate Social Responsibility (CSR) with a notable score improvement both in the Social and Ethics categories.EcoVadis ratings are based on international CSR standards  such as the Ten Principles of the United Nations Global Compact  the conventions of the International Labour Organization (ILO)  the Global Reporting Initiative (GRI) and ISO 260000. These ratings provide an evidence-based analysis of performance and an actionable roadmap for continuous improvement. Each company is assessed on key issues according to its size  location and business sector.Caroline PETIGNY  AFYREN's Chief Sustainability Officer  stated: ""We are delighted to have improved our Ecovadis score and maintained our silver medal this year  despite a more demanding set of criteria. Throughout its development  AFYREN continues its progress in terms of CSR and wishes to increase its impact. Sustainability is core to our value proposition  but we are striving to go even further  combining industrial development with best practices in terms of environmental and social responsibility.""About EcoVadisEcoVadis is the world's leading platform for assessing and rating corporate sustainability performance. It offers innovative solutions for measuring  monitoring and improving the CSR practices of companies worldwide. Its main objective is to promote CSR by assessing performance using a rigorous methodology and transparent rating criteria. More than 130 000 companies in over 180 countries have been assessed by EcoVadis. The EcoVadis evaluation takes into account 21 CSR criteria divided into four fundamental themes: Social Environment  Human Rights  Ethics and Responsible Purchasing.About AFYRENAFYREN is a French greentech company launched in 2012 to meet the challenge of decarbonizing industrial supplies. Its natural  innovative and proprietary fermentation technology valorizes local biomass from non-food agricultural co-products  replacing petro-sourced ingredients usually used in many product formulations. AFYREN's 100% biobased  low-carbon and sustainable solutions can meet decarbonization challenges in a wide variety of strategic sectors: human and animal nutrition  flavors and fragrances  life sciences and materials  and lubricants and technical fluids. AFYREN's plug-and-play  circular technology combines sustainability and competitiveness  with no need for manufacturers to change their processes.The Group's first French plant  AFYREN NEOXY  a joint venture with Bpifrance's SPI fund  is located in the Grand-Est region of France  in Saint Avold  serving mainly the European market.AFYREN is also pursuing a project in Thailand with a world leader in the sugar industry  and is developing its presence in the Americas  following up on distribution agreements it has already signed.At the end of 2023  the AFYREN Group employed about 120 people in Lyon  Clermont-Ferrand and Carling Saint-Avold. The company invests 20% of its annual budget in R&D to further develop its sustainable solutions.AFYREN has been listed on the Euronext (EPA: ) Growth ¬Æ exchange in Paris since 2021 (ISIN code: FR0014005AC9  mnemonic: ALAFY).Find out more: afyren.comView source version on businesswire.com: https://www.businesswire.com/news/home/20241118771742/en/AFYRENDirector for ESG  Communications and Public AffairsCaroline Petignycaroline.petigny@afyren.comInvestor RelationsMark Reinhardinvestisseurs@afyren.comNewCapInvestor RelationsTh√É¬©o Martin / Mathilde BohinTel: 01 44 71 94 94afyren@newcap.euNewCapMedia RelationsNicolas M√É¬©rigeau / Ga√É¬´lle FromaigeatTel: 01 44 71 94 98afyren@newcap.euSource: AFYREN",neutral,0.11,0.88,0.0,positive,0.76,0.24,0.0,True,English,"['Silver Medal', 'Improved Score', 'AFYREN', 'ECOVADIS', 'Investing', 'com', 'United Nations Global Compact', 'independent CSR assessment platforms', 'Global Reporting Initiative', 'International Labour Organization', 'four fundamental themes', 'food agricultural co-products', 'many product formulations', 'first French plant', 'Th√É¬©o Martin', 'Nicolas M√É¬©rigeau', 'Ga√É¬´lle Fromaigeat', 'unique fermentation technology', 'proprietary fermentation technology', 'Chief Sustainability Officer', 'global rating platform', 'international CSR standards', 'biobased, low-carbon ingredients', 'Corporate Social Responsibility', 'French greentech company', 'notable score improvement', 'transparent rating criteria', 'The EcoVadis evaluation', 'corporate sustainability performance', 'NewCap Media Relations', 'sustainability ratings leader', '100% biobased, low-carbon', 'circular technology', 'continuous improvement', 'leading platform', 'petro-sourced ingredients', 'The Group', 'Investor Relations', 'silver rating', 'BUSINESS WIRE', 'circular model', 'silver medal', 'last year', 'second year', 'industrial sector', 'demanding set', 'continuous efforts', 'Ten Principles', 'evidence-based analysis', 'actionable roadmap', 'key issues', 'business sector', 'value proposition', 'best practices', 'innovative solutions', 'CSR practices', 'main objective', 'rigorous methodology', 'Social Environment', 'Responsible Purchasing', 'industrial supplies', 'natural, innovative', 'local biomass', 'sustainable solutions', 'decarbonization challenges', 'wide variety', 'strategic sectors', 'animal nutrition', 'life sciences', 'technical fluids', 'joint venture', 'SPI fund', 'Grand-Est region', 'Saint Avold', 'European market', 'world leader', 'sugar industry', 'distribution agreements', 'Carling Saint-Avold', 'annual budget', 'R&D', 'ISIN code', 'Public Affairs', 'Mark Reinhard', 'Mathilde Bohin', '21 CSR criteria', 'sustainable development', 'Medium-sized company', 'industrial development', 'Regulatory News', 'Ethics categories', 'Human Rights', 'source version', 'EcoVadis ratings', 'Caroline PETIGNY', 'AFYREN NEOXY', 'AFYREN Group', 'AFYREN Director', 'Ecovadis score', '7 points', 'companies', 'CLERMONT-FERRAND', 'France', 'LYON', 'Paris', 'ALAFY', 'manufacturers', 'row', 'terms', 'change', 'category', 'Small', 'recognition', 'conventions', 'ILO', 'ISO', 'location', 'progress', 'impact', 'environmental', 'More', '180 countries', 'account', 'flavors', 'fragrances', 'materials', 'lubricants', 'play', 'competitiveness', 'need', 'processes', 'project', 'Thailand', 'presence', 'Americas', '120 people', 'Euronext', 'EPA', 'businesswire', 'Communications', 'Tel', '01']",2024-11-19,2024-11-20,investing.com
47098,EuroNext,NewsApi.org,https://www.investing.com/news/press-releases/ikonisys-completed-a-capital-increase-through-a-private-placement-93CH-3729334,Ikonisys Completed a Capital Increase Through a Private Placement By Investing.com,Ikonisys Completed a Capital Increase Through a Private Placement,"PARIS--(BUSINESS WIRE)--Regulatory News:Ikonisys SA ( Euronext (EPA: ) Growth Paris: ALIKO)  a company specializing in the early and accurate detection of cancers through a unique  fully automated solution for medical analysis laboratories (the Issuer)  today announces that it has completed a capital increase of ‚Ç¨200k  by way of a private placement.This operation is part of the ongoing series of recent capital increases aimed at strengthening the Company's financial stability and diversifying its shareholder structure. The net proceeds from the issuance  amounting to ‚Ç¨200k  will contribute to financing the working capital.Legal terms of the Capital IncreaseThe implementation of this capital increase  carried out with cancellation of shareholders' subscription rights through a private placement  was approved by the Board of Directors of the Issuer at its meeting held on November 12  2024 (the ""Capital Increase"").The new shares will be issued on the basis of the 16th resolution of the Issuer's shareholders' meeting held on September 30  2024. The settlement-delivery of the new shares will take place on November 19  2024.The Capital Increase did not require the approval of a notice (prospectus) by the Autorit√É¬© des march√É¬©s financiers (the AMF).Main terms of the Capital IncreaseThe Issuer has issued a total of 130 720 new ordinary shares  with a par value of ‚Ç¨0.5 each  to the investor  pursuant to article L. 411-2 1 ¬∞ of the French Monetary and Financial Code  in accordance with the 16th resolution passed by its Annual General Meeting on September 30  2024.The issuance price of the new shares issued under the Capital Increase  equal to ‚Ç¨1.53 per share  represents a premium of approximately 3% on the Ikonisys share price at the close of November 18  2024.Impact of the transaction in terms of liquidity risk management and financing horizonAs of December 31  2023  and as mentioned in the annual financial report published on July 8  2024  the Issuer's consolidated cash position amounted to ‚Ç¨9.4k.In order to strengthen its financial resources  Ikonisys completed a capital increase of ‚Ç¨1m on January 2  2024 and more recently four capital increases for a total cumulative sum of ‚Ç¨1m in June  July  August and October 2024.Taking into account these elements  the Capital Increase completed and the previously secured financing facility  the Company considers that it is now in a position to meet its financing needs for more than 12 months.Impact of the Capital Increase on a shareholder holding 1% of the capitalOn the basis of the 11 130 765 shares outstanding  the impact on the shareholding of a shareholder holding 1% of the Issuer's capital prior to the transaction is as follows:On a non-diluted basis On a diluted basis1 Before completion of the Capital Increase 1.00% 0.82% After issuance of the 130 720 shares resulting from the Capital Increase 0.99% 0.81%1 Dilution takes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum indicative number of 2 397 043 new shares (including the issuance of 2 000 000 for the closing of Hospitex International's acquisition).Capital breakdown before and after completion of the Capital IncreaseBefore the Capital Increase:Shareholder Number of shares % of share capital %of voting rights Cambria Co-Investment Fund 5 268 989 47.34% 54.64% Cambria Equity Partners 1 974 049 17.74% 21.15% MC Consulting 351 464 3.16% 4.05% Free float 3 536 263 31.77% 20.16% Total (EPA: ) 11 130 765 100% 100%Holding company of the CEO  Mario CrovettoAfter the Capital Increase:Shareholder Number of shares % of share capital %of voting rights Cambria Co-Investment Fund 5 268 989 46.79% 54.23% Cambria Equity Partners 1 974 049 17.53% 20.99% MC Consulting 351 464 3.12% 4.02% Free float 3 666 983 32.56% 20.76% Total 11 261 485 100% 100%Holding company of the CEO  Mario CrovettoRisk factors related to the IssuerDetailed information about the Issuer  including its business  financial information  results  outlook and related risk factors  is contained in the 2023 annual financial report for the financial year ended December 31  2023  published on July 8  2024. This document  together with other regulated information and all the Issuer's press releases  is available on the Issuer's website (www.ikonisys-finance.com).About IkonisysIkonisys SA is a cell-based diagnostics company based in Paris (France)  New Haven (Connecticut  USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops  produces and markets the proprietary Ikoniscope20 ¬Æ and Ikoniscope20max ¬Æ platforms  fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications  which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform  the company continues to develop a stream of new tests  including liquid biopsy tests based on Circulating Tumor Cells (CTC).For further information  please go to www.ikonisys.comDisclaimerThis press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense  the conditional tense and forward-looking words such as ""believe""  ""aim to""  ""expect""  ""intend""  ""estimate""  ""believe""  ""should""  ""could""  ""would"" or ""will"" or  where appropriate  the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data  assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic  financial  competitive and regulatory environment. This information contains data relating to the Company's intentions  estimates and objectives concerning  in particular  the market  strategy  growth  results  financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release  except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks  uncertainties or other factors that may affect its business  their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information  it being recalled that none of this forward-looking information constitutes a guarantee of actual results.View source version on businesswire.com: https://www.businesswire.com/news/home/20241118467529/en/IkonisysAlessandro MauriCFOinvestors@ikonisys.comNewCapLouis-Victor Delouvrier/Aur√É¬©lie ManavarereInvestor Relationsikonisys@newcap.euTel.: +33 (0)1 44 71 94 94NewCapNicolas MerigeauMedia Relationsikonisys@newcap.euTel.: +33 (0)1 44 71 94 98Source: Ikonisys SA",neutral,0.01,0.99,0.0,neutral,0.0,0.96,0.04,True,English,"['Capital Increase', 'Private Placement', 'Ikonisys', 'Investing', 'com', 'breakthrough fluorescence microscopy platform', 'unique, fully automated solution', 'several automated diagnostic applications', 'march√É¬©s financiers', 'outstanding dilutive instruments', 'Cambria Co-Investment Fund', 'Cambria Equity Partners', 'liquidity risk management', 'liquid biopsy tests', 'maximum indicative number', 'other regulated information', 'annual financial report', 'related risk factors', 'recent capital increases', 'four capital increases', 'medical analysis laboratories', 'Annual General Meeting', ""shareholders' subscription rights"", 'cell-based diagnostics company', '130,720 new ordinary shares', 'The Capital Increase', 'Ikonisys share price', 'automated solutions', 'new tests', 'financial information', ""shareholders' meeting"", 'voting rights', 'Detailed information', 'financial stability', 'Financial Code', 'financial resources', 'financial year', 'New Haven', 'Shareholder Number', 'working capital', 'Capital breakdown', 'share capital', 'Regulatory News', 'private placement', 'ongoing series', 'net proceeds', '16th resolution', 'par value', 'article L.', 'French Monetary', 'financing horizon', 'consolidated cash', 'cumulative sum', 'financing facility', 'financing needs', 'diluted basis1', 'Hospitex International', 'MC Consulting', 'Free float', 'Mario Crovetto', 'press releases', 'proprietary Ikoniscope20 ¬Æ', 'Ikoniscope20max ¬Æ platforms', 'reliable detection', 'FDA clearance', 'CE certification', 'new shares', 'shareholder structure', 'issuance price', 'Ikonisys SA', 'accurate detection', 'Legal terms', 'Main terms', 'The Issuer', 'shareholder holding', 'BUSINESS WIRE', 'rare cells', 'Growth Paris', 'Holding company', '11,130,765 shares', '130,720 shares', 'Euronext', 'EPA', 'ALIKO', 'early', 'cancers', 'way', 'operation', 'implementation', 'cancellation', 'Board', 'Directors', 'November', 'September', 'settlement-delivery', 'approval', 'notice', 'prospectus', 'Autorit√É¬©', 'AMF', 'total', 'investor', 'accordance', 'premium', 'close', 'Impact', 'transaction', 'December', 'July', 'order', 'January', 'June', 'August', 'October', 'account', 'elements', 'position', '12 months', 'shareholding', 'completion', '1 Dilution', 'exercise', 'closing', 'acquisition', 'CEO', 'results', 'outlook', 'document', 'website', 'ikonisys-finance', 'France', 'Connecticut', 'USA', 'Milan', 'Italy', 'Europe', 'stream', 'Circulati', '1 ¬∞']",2024-11-19,2024-11-20,investing.com
47099,EuroNext,NewsApi.org,https://www.irishtimes.com/business/2024/11/19/fbd-names-former-tirlan-ceo-as-next-chairman/,FBD names former Tirl√°n CEO as next chairman,Jim Bergin to take up post next May,Insurer FBD has named Tirl√°n‚Äôs former chief executive  Jim Bergin  as its next chairman  with effect from next May. Photograph: Nick BradshawInsurer FBD has named Tirl√°n‚Äôs former chief executive  Jim Bergin  as its next chairman  with effect from next May.He will succeed Liam Herlihy  who had signalled in the company‚Äôs latest annual report that he plans to step down at the conclusion of the 2025 annual general meeting on May 8th  2025  after completing nine years at the helm of the board.This is in line with the corporate governance standard promoted by the Irish stock market operator  Euronext Dublin.Mr Bergin joined Avonmore Co-operative Society in 1984. Following the company‚Äôs merger with Waterford Co-op in 1997 to form Glanbia plc  he went on to serve in a number of executive positions at group.READ MOREIn 2017  he became the chief executive of Glanbia‚Äôs then consumer and agribusiness joint venture with its main shareholder Glanbia Co-op. Glanbia subsequently sold its remaining shares in the venture to the co-op  which changed the name of the business from Glanbia Ireland to Tirl√°n two years ago.The 100 per cent farmer-owned Tirl√°n‚Äôs brands include Avonmore  Kilmeaden  Premier and Wexford in its portfolio  while its international brands include Gain Animal Nutrition  Truly Grass Fed  Millac and Solmiko.Mr Bergin retired from the company in July and was succeeded by internal candidate Se√°n Molloy.‚ÄúJim has a breadth of experience demonstrated through his highly successful career in the agri sector over the past 40 years ‚Äù said Mr Herlihy. ‚ÄúHe is well placed to lead the board of FBD into the future and I look forward to working with him through the coming months as he transitions into his new role.‚ÄùFBD reported in August that its pretax profit fell 18 per cent during the first half of the year to ‚Ç¨32 million  as an increase in motor damage and property claims more than offset the effect of a 10 per cent increase in gross written premiums  to ‚Ç¨226 million.Two-thirds of the premium increases were down to customers increasing their level of cover  it said. Storm Isha in January had resulted in ‚Äúsubstantially higher weather costs‚Äù  hitting its property result  FBD said.Still  the board approved a special dividend of ‚Ç¨1 per ordinary share  as its capital reserves ‚Äì or so-called solvency capital ‚Äì remained well above its own target and regulatory requirements.,neutral,0.01,0.99,0.0,mixed,0.47,0.22,0.32,True,English,"['former Tirl√°n CEO', 'next chairman', 'FBD', '100 per cent farmer-owned Tirl√°n', 'Irish stock market operator', '10 per cent increase', 'latest annual report', '2025 annual general meeting', 'corporate governance standard', 'Gain Animal Nutrition', 'Truly Grass Fed', 'gross written premiums', 'higher weather costs', 'Se√°n Molloy', 'former chief executive', 'Avonmore Co-operative Society', 'agribusiness joint venture', 'executive positions', 'next chairman', 'next May', 'Nick Bradshaw', 'Liam Herlihy', 'May 8th', 'nine years', 'Euronext Dublin', 'Mr Bergin', 'Waterford Co-op', 'main shareholder', 'remaining shares', 'internal candidate', 'successful career', 'agri sector', 'past 40 years', 'Mr Herlihy', 'coming months', 'new role', 'pretax profit', 'first half', 'motor damage', 'property claims', 'premium increases', 'Storm Isha', 'property result', 'special dividend', 'ordinary share', 'capital reserves', 'solvency capital', 'regulatory requirements', 'Jim Bergin', 'Glanbia plc', 'Glanbia Co-op', 'Glanbia Ireland', 'international brands', 'Insurer FBD', 'effect', 'Photograph', 'company', 'conclusion', 'helm', 'board', 'line', 'merger', 'number', 'group', 'READ', 'consumer', 'name', 'Kilmeaden', 'Premier', 'Wexford', 'portfolio', 'Millac', 'Solmiko', 'July', 'experience', 'future', 'August', 'Two-thirds', 'customers', 'level', 'cover', 'January', 'target']",2024-11-19,2024-11-20,irishtimes.com
47100,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983862/0/en/Cr%C3%A9dit-Agricole-Assurances-announces-the-launch-of-an-accelerated-bookbuilding-offering-in-Fran%C3%A7aise-des-Jeux-shares.html,Cr√©dit Agricole Assurances announces the launch of an accelerated bookbuilding offering in Fran√ßaise des Jeux shares,Cr√©dit Agricole Assurances announces the launch of an accelerated bookbuilding offering in Fran√ßaise des Jeux shares    19 November 2024 ‚Äì Cr√©dit......,Cr√©dit Agricole Assurances announces the launch of an accelerated bookbuilding offering in Fran√ßaise des Jeux shares19 November 2024 ‚Äì Cr√©dit Agricole Assurances (‚ÄúCAA‚Äù)  which  via its wholly-owned subsidiaries Predica and Cr√©dit Agricole Assurances Retraite  currently owns approximately 10.2 million shares of Fran√ßaise des Jeux (‚ÄúFDJ‚Äù  the ‚ÄúCompany‚Äù)  representing approximately 5.5% of the Company‚Äôs share capital and 7.3% of its voting rights  announces the launch  via Predica  of an offering of 4 073 436 ordinary shares of FDJ (the ‚ÄúShares‚Äù)  representing approximately 2.2% of the Company‚Äôs share capital. These Shares will be offered as part of an accelerated bookbuilding offering to institutional investors (the ‚ÄúPlacement‚Äù).CAA has been a shareholder of Fran√ßaise des Jeux since its IPO in November 2019 and has supported the Company throughout its development  including the successful recent acquisition of Kindred. FDJ becomes an international gaming operator. The Placement is part of CAA strategy in managing its investment portfolio. Upon completion of the Placement  CAA will hold approximately 3.3% of the Company‚Äôs share capital and 4.5% of the Company‚Äôs voting rights. CAA will remain a Board member of the Company.CAA has agreed to a lock up agreement with Cr√©dit Agricole Corporate and Investment Bank (the ‚ÄúGlobal Coordinator and Bookrunner‚Äù) in respect of the remaining FDJ shares it holds following the Placement for a 90 day-period  from the settlement date of the Placement (subject to customary exceptions).The Placement will start immediately following this announcement. The final terms of the Placement will be determined and announced after the end of the bookbuilding process.Settlement of the Placement should take place on 22 November 2024.FDJ‚Äôs shares are listed on the regulated market of Euronext in Paris (ISIN code: FR0013451333).This press release does not constitute an offer or solicitation to purchase and the offering of the shares in FDJ does not constitute a public offering (except to institutional investors) in any country  including in France.Cr√©dit Agricole Corporate and Investment Bank is acting as sole Global Coordinator and Bookrunner on the Placement.About Cr√©dit Agricole AssurancesCr√©dit Agricole Assurances  France‚Äôs largest insurer  is the company of the Cr√©dit Agricole group  which brings together all the insurance businesses of Cr√©dit Agricole S.A. Cr√©dit Agricole Assurances offers a range of products and services in savings  retirement  health  personal protection and property insurance products and services. They are distributed by Cr√©dit Agricole‚Äôs banks in France and in 9 countries worldwide  and are aimed at individual  professional  agricultural and business customers. Cr√©dit Agricole Assurances has 5 800 employees. Its premium income (‚Äúnon-GAAP‚Äù) to the end of 2023 amounted to 37.2 billion euros.www.ca-assurances.comPress contactsNicolas Leviaux +33 (0)1 57 72 09 50 / 06 19 60 48 53Julien Bad√© +33 (0)1 57 72 93 40 / 07 85 18 68 05service.presse@ca-assurances.frDisclaimerThis press release is for information purposes only and does not  and shall not  constitute an offer to sell or a solicitation of an offer to buy or subscribe any securities nor a solicitation to offer to purchase or to subscribe securities in any jurisdiction and does not constitute a public offer other than the offering to qualified investors in any jurisdiction  including France.The sale of FDJ shares does not constitute a public offering other than to qualified investors in any jurisdiction  including in France.No communication and no information in respect of the sale by Cr√©dit Agricole Assurances of FDJ shares may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken in any jurisdiction where such steps would be required. The offer of sale of FDJ shares on behalf of Cr√©dit Agricole Assurances may be subject to specific legal or regulatory restrictions in certain jurisdictions. Cr√©dit Agricole Assurances  its shareholders and affiliates take no responsibility for any violation of any such restrictions by any person.European Economic AreaIn member states of the European Economic Area  this press release is an advertisement and is not a prospectus with the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017  as amended (the ‚ÄúProspectus Regulation‚Äù).With respect to the member states of the European Economic Area other than France (the ‚ÄúMember States‚Äù)  no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in one of such Member States. In Member States  this communication and any offer if made subsequently is directed exclusively at persons who are ‚Äúqualified investors‚Äù within the meaning of Article 2(e) of the Prospectus Regulation.FranceIn France  the offer of FDJ shares described in this press release will be carried out through a placement through an accelerated bookbuilding process to qualified investors only within the meaning of Article 2(e) of the Prospectus Regulation and in accordance with applicable French laws and regulations. There will be no public offering in any country (including France) in connection with the shares of FDJ  except to qualified investors only.United KingdomIn the United Kingdom  this communication is for distribution to  and is only directed at  persons in the United Kingdom that (i) are ‚Äúinvestment professionals‚Äù falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended  the ‚ÄúOrder‚Äù)  (ii) are persons falling within article 49(2)(a) to (d) (‚Äúhigh net worth companies  unincorporated associations  etc.‚Äù) of the Order  or (iii) are located outside the United kingdom  or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Order) in connection with the issue or sale of any securities may otherwise lawfully be communicated or cause to be communicated (all such persons together being referred to as ‚ÄúRelevant Persons‚Äù). This press release is only directed at Relevant Persons and are available only to Relevant Persons. Any person who is not a Relevant Person must act or rely on this document or any of its contents.Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person shall not act or rely on this document or any of its contents.With respect to the United Kingdom  securities may not be offered or sold absent the publication of a prospectus in the United Kingdom or an exemption from such publication under the Regulation (EU) 2017/1129  as amended  as it forms part of domestic law by virtue of the European Union (Withdrawal Act) 2018 (the ‚ÄúUK Prospectus Regulation‚Äù). As a consequence  this document is directed only at persons who are ‚Äúqualified investors‚Äù as defined in point (e) of Article 2 of the UK Prospectus Regulation.This press release is not a prospectus which has been approved by the Financial Conduct Authority or any other United Kingdom regulatory authority for the purpose of Section 85 of the Financial Services and Markets Act 2000.United StatesThis press release does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities referred to in this announcement have not been  and will not be  registered under the U.S. Securities Act of 1933 (the ‚ÄúSecurities Act‚Äù) and may not be offered or sold in the United States absent such registration or an applicable exemption from the registration requirements of the Securities Act. FDJ shares have not been and will not be registered under the Securities Act and neither Cr√©dit Agricole Assurances  nor any of its shareholders or their respective affiliates intend to register any portion of the proposed offering in the United States or to conduct a public offering in the United States.Australia  Canada  Japan and South AfricaThe FDJ shares may not and will not be offered  sold or purchase in Australia  Canada  Japan or South Africa. The information contained in this press release does not constitute an offer of securities for sale in Australia  Canada  Japan or South Africa.The release  publication or distribution of this press release generally may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein should inform themselves about and observe any such restriction. No action has been taken to allow offer of FDJ shares or distribution of this press release in any jurisdiction where any such action would be required. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.Any investment decision to purchase FDJ shares must be made solely on the basis of publicly available information regarding FDJ. Such information is not the responsibility of Cr√©dit Agricole Assurances and has not been independently verified by Cr√©dit Agricole Assurances.The sole global coordinator and bookrunner is acting on behalf of Cr√©dit Agricole Assurances (to the exclusion of all others) in connection with the placement and will not be liable to any person other than Cr√©dit Agricole Assurances either for warranties given to clients of the sole global coordinator and bookrunner or for advice in connection with the placement.Neither the sole global coordinator and bookrunner nor any of its directors  officers  employees  advisors or agents accept any responsibility for  or make any representations or warranty  express or implied  as to the accuracy or completeness of the information contained in this press release (or if any information has been omitted from this press release) or any other information relating to FDJ  Cr√©dit Agricole Assurances  their respective subsidiaries or associated companies  whether in written  oral  visual or electronic form  and however transmitted or made available  or any loss from the use of this press release or its contents or otherwise.Distribution  publication or release of this press release are forbidden in any jurisdiction where such distribution or release would be unlawful.Attachment,neutral,0.01,0.99,0.0,negative,0.0,0.48,0.52,True,English,"['Cr√©dit Agricole Assurances', 'accelerated bookbuilding offering', 'Fran√ßaise des', 'Jeux shares', 'launch', 'Cr√©dit Agricole S.A.', 'Cr√©dit Agricole Assurances Retraite', 'Fran√ßaise des Jeux shares', 'Cr√©dit Agricole Corporate', 'Cr√©dit Agricole group', 'successful recent acquisition', 'international gaming operator', 'lock up agreement', 'European Economic Area', 'sole Global Coordinator', 'property insurance products', 'accelerated bookbuilding offering', 'remaining FDJ shares', 'European Parliament', 'insurance businesses', 'bookbuilding process', '10.2 million shares', '4,073,436 ordinary shares', 'These Shares', 'share capital', 'voting rights', 'investment portfolio', 'Board member', 'Investment Bank', 'customary exceptions', 'final terms', 'regulated market', 'ISIN code', 'press release', 'largest insurer', 'personal protection', 'business customers', 'premium income', '37.2 billion euros', 'Press contacts', 'Nicolas Leviaux', 'Julien Bad√©', 'specific legal', 'member states', 'institutional investors', 'qualified investors', 'public offering', 'settlement date', 'information purposes', 'regulatory restrictions', 'The Placement', 'CAA strategy', 'Prospectus Regulation', 'launch', 'owned', 'subsidiaries', 'Predica', 'Company', 'part', 'shareholder', 'IPO', 'November', 'development', 'Kindred', 'completion', 'Bookrunner', 'respect', '90 day-period', 'announcement', 'end', 'Euronext', 'Paris', 'solicitation', 'country', 'France', 'range', 'services', 'savings', 'retirement', 'health', 'banks', '9 countries', 'agricultural', '5,800 employees', 'GAAP', 'presse', 'ca-assurances', 'Disclaimer', 'securities', 'jurisdiction', 'sale', 'communication', 'registration', 'approval', 'steps', 'behalf', 'affiliates', 'responsibility', 'violation', 'advertisement', 'meaning', 'Council', '14 June', 'action', 'order', 'publication', 'persons', 'Article', '06']",2024-11-19,2024-11-20,globenewswire.com
47101,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983280/0/en/Progress-on-share-buyback-programme.html,Progress on share buyback programme,Progress on share buyback programme  ING announced today that  as part of our ‚Ç¨2.0 billion share buyback programme announced on 31 October 2024  in...,Progress on share buyback programmeING announced today that  as part of our ‚Ç¨2.0 billion share buyback programme announced on 31 October 2024  in total 5 545 654 shares were repurchased during the week of 11 November 2024 up to and including 15 November 2024.The shares were repurchased at an average price of ‚Ç¨14.88 or a total amount of ‚Ç¨82 507 552.62. For detailed information on the daily repurchased shares  individual share purchase transactions and weekly reports  see the ING website at share buy back programme.In line with the purpose of the programme to reduce the share capital of ING  the total number of shares repurchased under this programme to date is 17 265 983 ordinary shares at an average price of ‚Ç¨15.26 for a total consideration of EUR 263 545 880.39. To date approximately 13.18% of the maximum total value of the share buyback programme has been completed.Note for editorsFor more on ING  please visit www.ing.com. Frequent news updates can be found in the Newsroom or via X @ING_news feed. Photos of ING operations  buildings and its executives are available for download at Flickr.Press enquiries Investor enquiries Christoph Linke ING Group Investor Relations +31 20 576 5000 +31 20 576 6396 Christoph.Linke@ing.com Investor.Relations@ing.comING PROFILEING is a global financial institution with a strong European base  offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank‚Äôs more than 60 000 employees offer retail and wholesale banking services to customers in over 40 countries.ING Group shares are listed on the exchanges of Amsterdam (INGA NA  INGA.AS)  Brussels and on the New York Stock Exchange (ADRs: ING US  ING.N).ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers  which give updates on them annually. ING's ESG rating by MSCI was reconfirmed by MSCI as 'AA' in August 2024 for the fifth year. As of December 2023  in Sustainalytics‚Äô view  ING‚Äôs management of ESG material risk is ‚ÄòStrong‚Äô. Our current ESG Risk Rating  is 17.2 (Low Risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext  STOXX  Morningstar and FTSE Russell. Society is transitioning to a low-carbon economy. So are our clients  and so is ING. We finance a lot of sustainable activities  but we still finance more that‚Äôs not. Follow our progress on ing.com/climate.Important legal informationElements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‚ÄòMarket Abuse Regulation‚Äô).ING Group‚Äôs annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‚ÄòIFRS- EU‚Äô). In preparing the financial information in this document  except as described otherwise  the same accounting principles are applied as in the 2023 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.Certain of the statements contained herein are not historical facts  including  without limitation  certain statements made of future expectations and other forward-looking statements that are based on management‚Äôs current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to diÔ¨Äer materially from those expressed or implied in such statements. Actual results  performance or events may diÔ¨Äer materially from those in such statements due to a number of factors  including  without limitation: (1) changes in general economic conditions and customer behaviour  in particular economic conditions in ING‚Äôs core markets  including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets  including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‚Äòbenchmark‚Äô indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally  including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non-compliance with or changes in laws and regulations  including those concerning financial services  financial economic crimes and tax laws  and the interpretation and application thereof (11) geopolitical risks  political instabilities and policies and actions of governmental and regulatory authorities  including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations  including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING‚Äôs ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes  including write down and conversion powers in relation to our securities (17) outcome of current and future litigation  enforcement proceedings  investigations or other regulatory actions  including claims by customers or stakeholders who feel misled or treated unfairly  and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws  including FATCA (19) operational and IT risks  such as system disruptions or failures  breaches of security  cyber-attacks  human error  changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete  inaccurate  or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the eÔ¨Äects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy  including such risks and challenges as a consequence of the use of emerging technologies  such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors  including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business  operational  regulatory  reputation  transition and other risks and challenges in connection with climate change and ESG-related matters  including data gathering and reporting (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks  including in connection with use of models  use of derivatives  or maintaining appropriate policies and guidelines (29) changes in capital and credit markets  including interbank funding  as well as customer deposits  which provide the liquidity and capital required to fund our operations  and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING‚Äôs more recent disclosures  including press releases  which are available on www.ING.com.This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information  internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy  completeness  reasonableness or reliability of such information.Materiality  as used in the context of ESG  is distinct from  and should not be confused with  such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‚ÄòSEC‚Äô) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition  there is currently no single  globally recognized set of accepted definitions in assessing whether activities are ‚Äúgreen‚Äù or ‚Äúsustainable.‚Äù Without limiting any of the statements contained herein  we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security  use of proceeds  a description of applicable project(s) and/or any other relevant information  please reference the offering documents for such security.This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only  and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of  or take any responsibility for  any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document  or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING‚Äôs control.Any forward-looking statements made by or on behalf of ING speak only as of the date they are made  and ING assumes no obligation to publicly update or revise any forward-looking statements  whether as a result of new information or for any other reason.This document does not constitute an oÔ¨Äer to sell  or a solicitation of an oÔ¨Äer to purchase  any securities in the United States or any other jurisdiction.Attachment,neutral,0.44,0.55,0.01,mixed,0.25,0.02,0.73,True,English,"['share buyback programme', 'Progress', 'Christoph Linke ING Group Investor Relations', '2023 ING Group consolidated annual accounts', 'New York Stock Exchange', 'individual share purchase transactions', 'ING Groep N.V.', 'International Financial Reporting Standards', 'operating company ING Bank', 'ING Bank N.V.', '‚Ç¨2.0 billion share buyback programme', 'current ESG Risk Rating', 'share buyback programme ING', 'currency exchange rates', 'international response measures', 'ESG material risk', 'ESG index products', 'same accounting principles', 'global economic impact', 'state compensation schemes', 'global financial institution', 'financial economic crimes', 'strong European base', 'Market Abuse Regulation', 'major market participant', 'general economic conditions', 'particular economic conditions', 'maximum total value', 'Frequent news updates', 'Important legal information', 'related market disruption', 'ING Group shares', 'wholesale banking services', 'other forward-looking statements', 'Investor enquiries', 'ESG rating', 'share capital', 'Low Risk', 'current views', 'financial services', 'financial information', 'financial markets', 'EU Regulation', 'European Union', 'ING website', 'ING operations', 'ING PROFILE', 'ING US', 'average price', 'total amount', 'detailed information', 'daily repurchased', 'weekly reports', 'total consideration', 'Press enquiries', 'INGA NA', 'INGA.AS', 'independent research', 'ratings providers', 'fifth year', 'Sustainalytics‚Äô view', 'major sustainability', 'leading providers', 'FTSE Russell', 'low-carbon economy', 'sustainable activities', 'press release', 'IFRS- EU', 'Small differences', 'historical facts', 'future expectations', 'unknown risks', 'actual results', 'customer behaviour', 'core markets', 'rate levels', 'developing markets', 'fiscal uncertainty', 'United States', 'principal markets', 'capital markets', 'counterparty creditworthiness', 'geopolitical risks', 'political instabilities', 'regulatory authorities', '17,265,983 ordinary shares', 'total number', 'tax laws', '5,545,654 shares', 'Progress', '31 October', '11 November', '15 November', 'line', 'purpose', 'Note', 'editors', 'Newsroom', 'Photos', 'buildings', 'executives', 'download', 'Flickr', 'people', 'life', 'business', '60,000 employees', 'retail', 'customers', '40 countries', 'exchanges', 'Amsterdam', 'Brussels', 'ADRs', 'heart', 'policies', 'MSCI', 'AA', 'August', 'December', 'management', 'examples', 'Euronext', 'STOXX', 'Morningstar', 'Society', 'clients', 'lot', 'Elements', 'meaning', 'Article', 'accordance', 'document', 'figures', 'tables', 'rounding', 'limitation', 'assumptions', 'uncertainties', 'performance', 'events', 'factors', 'regional', 'invasion', 'Russia', 'Ukraine', 'interest', 'default', 'discontinuation', 'benchmark', 'indices', 'inflation', 'deflation', 'borrower', 'failures', 'banks', 'scope', 'compliance', 'regulations', 'interpretation', 'application', 'governmental', 'connection']",2024-11-19,2024-11-20,globenewswire.com
47102,EuroNext,NewsApi.org,https://www.investing.com/news/press-releases/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity-93CH-3729315,Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity By Investing.com,Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity,Dapirolizumab pegol (DZP) met its primary endpoint  demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA  an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic  debilitating autoimmune disease affecting multiple organ systems  primarily in women  for whom there is a significant need for additional treatment optionsBRUSSELS  Belgium and CAMBRIDGE  Mass.  Nov. 19  2024 (GLOBE NEWSWIRE) -- UCB ( Euronext (EPA: ) Brussels: UCB) and Biogen Inc. (NASDAQ: NASDAQ: ) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP)  a novel Fc-free anti-CD40L drug candidate  demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). The results were shared during an oral  late-breaker presentation at ACR Convergence 2024  the American College of Rheumatology's annual meeting  in Washington  DC.There remains a significant unmet need for additional treatment options for people living with systemic lupus erythematosus and the results we observed in PHOENYCS GO suggest dapirolizumab pegol has the potential to be impactful for this chronic and debilitating autoimmune disease. Across clinical endpoints we observed a positive effect and a favorable safety profile  said Megan E.B. Clowse  M.D.  principal investigator of the study and Associate Professor of Medicine  Chief of the Division of Rheumatology and Immunology at Duke University School of Medicine. Participants receiving dapirolizumab pegol experienced reduced lupus activity while also tapering steroids  changes important to people living with the disease.In the PHOENYCS GO study (n=321)  dapirolizumab pegol (DZP) was administered intravenously every four weeks. On the primary endpoint measuring improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks  study participants receiving DZP plus SOC had a statistically significant 14.6% (95% confidence interval [CI]: 3.3  25.8; p=0.0110) higher response rate (49.5%) than those receiving SOC alone (34.6%). A higher BICLA response rate reflects a treatment response across all affected organs at baseline and is associated with meaningful clinical benefit.On the first secondary endpoint of BICLA response at Week 24  study participants receiving DZP plus SOC had a 7.9% higher response rate (46.6%) than those receiving SOC alone (38.3%). However  the difference did not reach statistical significance (95% CI: -3.6  19.4; p=0.1776). Given statistical significance was not achieved for the first key secondary endpoint in the hierarchical testing  analyses for all the subsequent secondary endpoints are descriptive and nominal p-values are included.Subsequent analyses of additional secondary endpoints showed clinical improvements in the DZP group  including SLE Responder Index (SRI)-4 response  corticosteroid tapering  SLE Disease Activity Index-2K (SLEDAI-2K)  achievement of Lupus Low Disease Activity State (LLDAS) and prevention of severe BILAG flares:17.1% more participants receiving DZP were able to reduce their corticosteroid dose from >7.5 mg/day prednisone equivalent at baseline to ‚Ä∞¬§7.5 mg/day at Week 48 (72.4% vs. 52.9%; difference [95% CI]: 17.1% [0.7  33.4]; nominal p=0.0404).18.8% higher SRI-4 response rate at Week 48 (95% CI: 7.3  30.3; nominal p=0.0014) among study participants who received DZP plus SOC (60.1%) versus those who received SOC alone (41.1%).A 1.8-fold greater decrease from baseline in SLEDAI-2K in study participants receiving DZP plus SOC compared to SOC alone at Week 48 (-6.1 vs ‚Äú4.2; difference [95% CI]: -1.8 [-2.7  -0.9]; nominal p=0.0001).A 20.9% greater proportion of participants in the DZP group achieved LLDAS at Week 48 compared to SOC alone (40.9% vs. 19.6%; difference [95% CI]: 20.9% [10.7 31.2]; nominal p<0.001).Participants receiving DZP plus SOC had 50% fewer severe BILAG flares through Week 48 (95% CI: 1.4  21.6; nominal p=0.0257) compared to SOC alone (11.6% vs. 23.4%).Due to the varied symptoms and severity by patient  progress in the treatment of lupus has historically been challenging. With dapirolizumab pegol  we believe that our differentiated approach that targets the CD40L pathway results in clinically meaningful improvements across multiple disease domains and could substantially impact the burden of this disease in particular for women  who are disproportionately affected by lupus  said Fiona du Monceau  Head of Patient Evidence at UCB. We are highly encouraged by the results we have seen in PHOENYCS GO and are excited to continue the clinical development of dapirolizumab pegol in the second Phase 3 study  PHOENYCS FLY.The safety profile of dapirolizumab pegol was generally favorable. The safety results were consistent with previous DZP studies and with that in study participants with SLE receiving an immunomodulator. In the PHOENYCS GO study  a higher proportion of patients receiving DZP plus SOC had treatment-emergent adverse events (TEAEs) compared to SOC alone (82.6% vs. 75.0%). The proportion of participants with serious TEAEs was 9.9% in those participants receiving DZP plus SOC compared to 14.8% in those receiving SOC alone. Opportunistic infections were reported in 2.8% of participants receiving DZP plus SOC compared to 0.9% of those receiving SOC alone. Discontinuation of treatment or study participation due to TEAEs occurred in 4.7% (10) of participants receiving DZP plus SOC and 3.7% (4) of participants receiving SOC alone.At Biogen  we understand that lupus affects everyone differently and are committed to developing treatments as diverse as the patients we serve  said Diana Gallagher  MD  Head of AD  MS and Immunology Development Units at Biogen. These results reinforce our belief that dapirolizumab pegol has the potential to change the approach to care of SLE and we are dedicated to advancing this program with our partner UCB.Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study. In 2024  UCB and Biogen will initiate a second Phase 3 trial of dapirolizumab pegol  PHOENYCS FLY (NCT06617325).The safety and efficacy of dapirolizumab pegol in systemic lupus erythematosus have not been established  and it is not approved for use in systemic lupus erythematosus by any regulatory authority worldwide.About Systemic Lupus Erythematosus (SLE)SLE is a chronic  multifactorial autoimmune disease that is caused by the activation of autoreactive T  B and antigen-presenting cells  resulting in manifestations across multiple organ systems with periods of illness or flares alternating with periods of inactivity.1 SLE can present itself in several ways including rash  arthritis  anemia  thrombocytopenia  serositis  nephritis  seizures or psychosis.2 SLE is associated with a greater risk of death from causes such as infection and cardiovascular disease.An estimated 90% of people living with lupus are women; most begin to see symptoms between the ages of 15-55.3 4 5 Individuals from populations of African  Hispanic  Asian and Native American descent are at a greater risk of earlier onset and more aggressive disease.6 7 Pregnancy in women with SLE is high risk  with higher maternal and fetal mortality and morbidity than the general population.8 9About Dapirolizumab PegolDapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment. Dapirolizumab pegol inhibits CD40L signaling which has been shown to reduce B cell activation and autoantibody production  mitigate type 1 interferon (IFN) secretion  and attenuate T cell and antigen-presenting cell (APC) activation.10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.11About UCBUCB  Brussels  Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB is listed on Euronext Brussels (symbol: UCB).About BiogenFounded in 1978  Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks  balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow us on social media - Facebook  LinkedIn  X  YouTube.Forward looking statements UCBThis press release may contain forward-looking statements including  without limitation  statements containing the words believes  anticipates  expects  intends  plans  seeks  estimates  may  will  continue and similar expressions. These forward-looking statements are based on current plans  estimates and beliefs of management. All statements  other than statements of historical facts  are statements that could be deemed forward-looking statements  including estimates of revenues  operating margins  capital expenditures  cash  other financial information  expected legal  arbitration  political  regulatory or clinical results or practices and other such estimates and results. By their nature  such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks  uncertainties and assumptions which might cause the actual results  financial condition  performance or achievements of UCB  or industry results  to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic  business and competitive conditions  the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing  costs associated with research and development  changes in the prospects for products in the pipeline or under development by UCB  effects of future judicial decisions or governmental investigations  safety  quality  data integrity or manufacturing issues; potential or actual data security and data privacy breaches  or disruptions of our information technology systems  product liability claims  challenges to patent protection for products or product candidates  competition from other products including biosimilars  changes in laws or regulations  exchange rate fluctuations  changes or uncertainties in tax laws or the administration of such laws  and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline  will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far  the complexity of the human body cannot be reproduced in computer models  cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products  which are the subject of partnerships  joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe  effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also  UCB or others could discover safety  side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover  sales may be impacted by international and domestic trends toward managed care and health care cost containment  including pricing pressure  political and public scrutiny  customer and prescriber patterns or practices  and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally  a breakdown  cyberattack or information security breach could compromise the confidentiality  integrity and availability of UCB's data and systems.Given these uncertainties  you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market  or at any particular time  nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.UCB is providing this information  including forward-looking statements  only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release  either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events  conditions or circumstances on which any such statement is based  unless such statement is required pursuant to applicable laws and regulations.Additionally  information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities  nor shall there be any offer  solicitation or sale of securities in any jurisdiction in which such offer  solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.Biogen Safe HarborThis news release contains forward-looking statements  including but not limited to those relating to the potential benefits  safety and efficacy of DZP; the timing and status of current and future regulatory filings; risks and uncertainties associated with drug development and commercialization; the potential of Biogen's commercial business and pipeline programs; the anticipated benefits and potential of Biogen's collaboration arrangements with UCB; Biogen's strategy and plans; and potential cost healthcare savings related to biosimilars. These forward-looking statements may be accompanied by words such as aim  anticipate  believe  could  estimate  expect  forecast  intend  may  plan  potential  possible  will  would and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk  and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements  including without limitation  actual timing and content of submissions to and decisions made by the regulatory authorities regarding DZP; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies  or may fail or refuse to approve or may delay approval of DZP; risks of unexpected costs or delays or other unexpected hurdles; uncertainty of success in the development and potential commercialization of DZP  which may be impacted by  among other things  the level of preparedness of healthcare providers to treat patients  difficulties in obtaining or changes in the availability of reimbursement for DZP and other unexpected difficulties or hurdles; the occurrence of adverse safety events; unexpected concerns that may arise from additional data or analysis; failure to protect and enforce data  intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; risks of legal actions  regulatory scrutiny or other challenges to biosimilars  results of operations and financial condition; product liability claims; and third party collaboration risks. The foregoing sets forth many  but not all  of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen's current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.References:Tselios K  Gladman DD  Touma Z  et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114-122. Fanouriakis A  Tziolos N  Bertsias G  et al. Update √é¬øn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi:10.1136/annrheumdis-2020-218272 Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2002;16(5):847-58. Epub 2002/12/11. doi: 10.1053/berh.2002.0259. PubMed PMID: 12473278. Rees F  Doherty M  Grainge M  Davenport G  Lanyon P  Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK  1999-2012. Ann Rheum Dis. 2016;75(1):136-41. Epub 2014/10/01. doi: 10.1136/annrheumdis-2014-206334. PubMed PMID: 25265938; PubMed Central PMCID: PMCPMC4717400. Pons-Estel GJ  Ugarte-Gil MF  Alarc√É¬≥n GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799-814. Carter EE  Barr SG  Clarke AE. The global burden of SLE: prevalence  health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. Epub 2016/08/26. doi: 10.1038/nrrheum.2016.137. PubMed PMID: 27558659. Kheir JM  Guthridge CJ  Johnston JR  Adams LJ  Rasmussen A  Gross TF  et al. Unique clinical characteristics  autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000247. Epub 2018/03/14. doi: 10.1136/lupus-2017-000247. PubMed PMID: 29531773; PubMed Central PMCID: PMCPMC5844376. Mehta B  Luo Y  Xu J  Sammaritano L  Salmon J  Lockshin M  et al. Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis. Ann Intern Med. 2019;171(3):164-71. Epub 2019/07/10. doi: 10.7326/M19-0120. PubMed PMID: 31284305. Bitencourt N  Bermas BL. Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception  Pregnancy and Breastfeeding. Paediatr Drugs. Furie RA  Bruce IN  D√É¬∂rner T  et al. Phase 2 randomized  placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford).2021;60(11): 5397-407. Clinicaltrials.gov (NCT04294667). A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO) 2023 [cited August 2024] Available at: https://clinicaltrials.gov/ct2/showithNCT04294667. Retrieved July 25  2024.MEDIA CONTACTS:UCBAdriaan Snauwaert+32 497 70 23 46Adriaan.snauwaert@ucb.comBiogenJack Cox+1 781 464 3260public.affairs@biogen.comINVESTOR CONTACTS:UCBAntje Witte+32 2 559 9414Antje.Witte@ucb.comBiogenStephen Amato+1 781 464 2442IR@biogen.comSource: Biogen Inc.,neutral,0.0,0.99,0.01,mixed,0.15,0.15,0.7,True,English,"['Systemic Lupus Erythematosus Disease Activity', 'Dapirolizumab Pegol Phase 3 Data', 'American College', 'Significant Reduction', 'Rheumatology', 'Investing', 'com', 'novel Fc-free anti-CD40L drug candidate', 'BILAG)-based Composite Lupus Assessment', 'British Isles Lupus Assessment Group', 'Lupus Low Disease Activity State', 'Megan E.B. Clowse', '50% fewer severe BILAG flares', '50% less severe disease flares', '18.8% higher SRI-4 response rate', 'severe systemic lupus erythematosus', 'first key secondary endpoint', 'chronic, debilitating autoimmune disease', 'SLE Disease Activity Index', 'higher BICLA response rate', 'Phase 3 PHOENYCS GO study', 'higher response rate', 'SLE Responder Index', 'first secondary endpoint', 'oral, late-breaker presentation', 'Duke University School', 'additional secondary endpoints', '>7.5 mg/day prednisone equivalent', 'Fiona du Monceau', 'moderate-to-severe disease activity', 'multiple disease domains', 'second Phase 3 study', 'subsequent secondary endpoints', '1.8-fold greater decrease', 'multiple clinical endpoints', 'additional treatment options', 'multiple organ systems', 'significant unmet need', 'favorable safety profile', 'meaningful clinical benefit', 'significant clinical improvement', 'lupus activity', 'greater response', 'significant need', 'treatment response', 'SRI)-4 response', 'PHOENYCS FLY', 'significant improvement', 'clinical improvements', 'meaningful improvements', 'clinical development', 'primary endpoint', '20.9% greater proportion', 'DZP group', 'Dapirolizumab pegol', 'GLOBE NEWSWIRE', 'Biogen Inc.', 'ACR Convergence', 'American College', 'annual meeting', 'positive effect', 'M.D.', 'principal investigator', 'Associate Professor', 'statistical significance', 'hierarchical testing', 'nominal p-values', 'Subsequent analyses', 'corticosteroid tapering', 'corticosteroid dose', 'varied symptoms', 'differentiated approach', 'CD40L pathway', 'study participants', 'Patient Evidence', 'detailed results', 'standard', 'care', 'women', 'BRUSSELS', 'Belgium', 'CAMBRIDGE', 'Mass.', 'UCB', 'Euronext', 'EPA', 'NASDAQ', 'people', 'Rheumatology', 'Washington', 'DC', 'potential', 'Medicine', 'Chief', 'Division', 'Immunology', 'steroids', 'changes', 'achievement', '48 weeks', 'organs', 'baseline', 'difference', 'SLEDAI', 'LLDAS', 'prevention', 'severity', 'progress', 'burden', 'Head', '52', '19.', '23.']",2024-11-19,2024-11-20,investing.com
47103,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/11/19/2983898/0/en/Volta-Finance-Limited-Net-Asset-Value-as-at-31-October-2024.html,Volta Finance Limited - Net Asset Value as at 31 October 2024,Volta Finance Limited (VTA / VTAS)October 2024 monthly reportNOT FOR RELEASE  DISTRIBUTION  OR PUBLICATION  IN WHOLE OR PART  IN OR INTO THE UNITED STATES...,"Volta Finance Limited (VTA / VTAS)October 2024 monthly reportNOT FOR RELEASE  DISTRIBUTION  OR PUBLICATION  IN WHOLE OR PART  IN OR INTO THE UNITED STATESGuernsey  November 19th  2024AXA IM has published the Volta Finance Limited (the ‚ÄúCompany‚Äù or ‚ÄúVolta Finance‚Äù or ‚ÄúVolta‚Äù) monthly report for October 2024. The full report is attached to this release and will be available on Volta‚Äôs website shortly (www.voltafinance.com).Performance and Portfolio ActivityDear Investors Volta Finance recorded a net performance of +4.3% in October bringing the year-to-date return to +18.4%. This performance was primarily achieved via our CLO Equity exposure that generated strong distributions while prices remained broadly flat.In terms of market activity  it felt like October displayed evidences of a ‚Äútransition month‚Äù  placed in between a very busy post summer run and the US presidential elections. The month was far from being non-eventful though  as the ECB reduced its depo rate by another 25bps to 3.25% while it became very clear that the Fed would cut its main rate by 25bps as well - which eventually happened early Novembre. Data dependency remained the preferred approach for both the Fed and the ECB despite both jurisdictions taking different paths in terms of employment  retail sales and company earnings.Credit markets were relatively stable during the period as supportive central bank actions were overall a tailwind for risky assets. High Yield indices in Europe (Xover) were marginally wider in the 310bps context while US CDX High-Yield settled at c. +335bps (1bps tighter MoM). On the Loan side  Euro Loans closed slightly higher  7 cents up at c. 97.65px (Morningstar European Leveraged Loan Index)  while their US counterparts closed at 96.97px (+27 cents up). Primary CLO markets remained extremely busy  we recorded circa USD 60bn of issuance in the US and almost EUR 10bn in Europe. Spreads moved sideways across the capital structure and trading volumes reduced into month-end  as the US election was approaching.Looking at fundamentals  both US and European default rates were slightly lower month-on-month respectively at 0.73% and 0.78% while the proportion of CCC-rated Loans within CLO collateral portfolios was slightly lower at 5.3% in US CLOs and slightly higher at 3.8% in Europe. Loan repayment rates continued to trend upwards at 27.4% in the US (flat YoY growth rate of the Loan market) and 14.2% in Europe (+6% YoY growth).Cashflow generation through the quarter was in line with Q3 2024 at c.‚Ç¨11m  running at the highs of the last 5 years. Still  it is worth noticing that some post reinvestment period CLO Equities showed reduced cashflows as a result of loan prepayments in their underlying portfolios. Over the last 6 month period  the cashflow generation remained strong at c.‚Ç¨29m equivalent of interests and coupons  representing c.21% of the month‚Äôs NAV on an annualized basis  post the recent uptick in Volta‚Äôs NAV.In terms of activity  we purchased 1 European CLO Equity in the secondary market for ‚Ç¨2.5m with a 15% target return and invested a net additional amount of $2m in US CLO BB tranches at 660bps discount margin over SOFR  in addition to $1.7m additional funding in our US CLO warehouse. It is also worth highlighting the prepayment of ‚Ç¨2m of our remaining bank balance sheet transaction (invested in 2018)  Volta being still exposed to a residual amount of ‚Ç¨0.1m as defaults are being workout. Volta is now 99% exposed to CLO (with cash to be reinvested in CLO).Through the month  Volta‚Äôs CLO Equity tranches (56% of Volta‚Äôs portfolio) returned a +5.5% performance** while CLO Debt tranches (39% of Volta‚Äôs portfolio) returned a +1.8% performance**  cash representing c.5% of NAV. The fund being c.26% exposed to USD  the recent appreciation of USD vs EUR had a positive impact of +0.7% on the overall performance.As of end of October 2024  Volta‚Äôs NAV was ‚Ç¨273.3m  i.e. ‚Ç¨7.47 per share.*It should be noted that approximately 4.16% of Volta‚Äôs GAV comprises investments for which the relevant NAVs as at the month-end date are normally available only after Volta‚Äôs NAV has already been published. Volta‚Äôs policy is to publish its NAV on as timely a basis as possible to provide shareholders with Volta‚Äôs appropriately up-to-date NAV information. Consequently  such investments are valued using the most recently available NAV for each fund or quoted price for such subordinated notes. The most recently available fund NAV or quoted price was 4.16% as at 30 September 2024.** ‚Äúperformances‚Äù of asset classes are calculated as the Dietz-performance of the assets in each bucket  taking into account the Mark-to-Market of the assets at period ends  payments received from the assets over the period  and ignoring changes in cross-currency rates. Nevertheless  some residual currency effects could impact the aggregate value of the portfolio when aggregating each bucket.CONTACTSFor the Investment ManagerAXA Investment Managers ParisFran√ßois Touatifrancois.touati@axa-im.com+33 (0) 1 44 45 80 22Olivier PonsOlivier.pons@axa-im.com+33 (0) 1 44 45 87 30Company Secretary and AdministratorBNP Paribas S.A  Guernsey Branchguernsey.bp2s.volta.cosec@bnpparibas.com+44 (0) 1481 750 853Corporate BrokerCavendish Securities plcAndrew WorneDaniel Balabanoff+44 (0) 20 7397 8900*****ABOUT VOLTA FINANCE LIMITEDVolta Finance Limited is incorporated in Guernsey under The Companies (Guernsey) Law  2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange's Main Market for listed securities. Volta‚Äôs home member state for the purposes of the EU Transparency Directive is the Netherlands. As such  Volta is subject to regulation and supervision by the AFM  being the regulator for financial markets in the Netherlands.Volta‚Äôs Investment objectives are to preserve its capital across the credit cycle and to provide a stable stream of income to its Shareholders through dividends that it expects to distribute on a quarterly basis. The Company currently seeks to achieve its investment objectives by pursuing exposure predominantly to CLO‚Äôs and similar asset classes. A more diversified investment strategy across structured finance assets may be pursued opportunistically. The Company has appointed AXA Investment Managers Paris an investment management company with a division specialised in structured credit  for the investment management of all its assets.*****ABOUT AXA INVESTMENT MANAGERSAXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group  a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with 2 700 professionals and ‚Ç¨844 billion in assets under management as of the end of December 2023.*****This press release is published by AXA Investment Managers Paris (‚ÄúAXA IM‚Äù)  in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU  the ‚ÄúAIFM Directive‚Äù) of Volta Finance Limited (the ""Volta Finance"") whose portfolio is managed by AXA IM.This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are ‚ÄúU.S. persons‚Äù for purposes of Regulation S under the U.S. Securities Act of 1933  as amended (the ‚ÄúSecurities Act‚Äù)  or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.*****This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ‚ÄúOrder‚Äù) or (iii) high net worth companies  and other persons to whom it may lawfully be communicated  falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ‚Äúrelevant persons‚Äù). The securities referred to herein are only available to  and any invitation  offer or agreement to subscribe  purchase or otherwise acquire such securities will be engaged in only with  relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.*****This press release contains statements that are  or may deemed to be  ""forward-looking statements"". These forward-looking statements can be identified by the use of forward-looking terminology  including the terms ""believes""  ""anticipated""  ""expects""  ""intends""  ""is/are expected""  ""may""  ""will"" or ""should"". They include the statements regarding the level of the dividend  the current market context and its impact on the long-term return of Volta Finance's investments. By their nature  forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance's actual results  portfolio composition and performance may differ materially from the impression created by the forward-looking statements. AXA IM does not undertake any obligation to publicly update or revise forward-looking statements.Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events  the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition  no assurance can be given that the investment objective will be achieved.The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review  the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance  as implemented by AXA IM. The historical success or AXA IM‚Äôs belief in the future success  of any of these trades or strategies is not indicative of  and has no bearing on  future results.The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.Editor: AXA INVESTMENT MANAGERS PARIS  a company incorporated under the laws of France  having its registered office located at Tour Majunga  6  Place de la Pyramide - 92800 Puteaux. AXA IMP is authorized by the Autorit√© des March√©s Financiers under registration number GP92008 as an alternative investment fund manager within the meaning of the AIFM Directive.*****Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.29,0.71,True,English,"['Volta Finance Limited', 'Net Asset Value', '31 October', 'remaining bank balance sheet transaction', 'Morningstar European Leveraged Loan Index', 'supportive central bank actions', 'busy post summer run', 'Fran√ßois Touati francois', 'AXA Investment Managers Paris', 'flat YoY growth rate', 'US CLO BB tranches', 'European default rates', '1 European CLO Equity', 'High Yield indices', '660bps discount margin', '7m additional funding', 'CLO Equity tranches', 'CLO Debt tranches', 'CLO Equity exposure', 'post reinvestment period', 'residual currency effects', 'Loan repayment rates', 'US presidential elections', 'US CDX High-Yield', 'Primary CLO markets', 'CLO collateral portfolios', 'net additional amount', 'US CLO warehouse', 'Volta Finance Limited', 'October 2024 monthly report', 'last 6 month period', 'residual amount', 'Loan side', 'loan prepayments', 'depo rate', 'main rate', 'cross-currency rates', 'CLO Equities', 'Loan market', 'Credit markets', 'last 5 years', 'underlying portfolios', 'AXA IM', 'full report', 'US counterparts', 'US election', 'US CLOs', 'UNITED STATES', 'Dear Investors', 'net performance', 'strong distributions', 'Data dependency', 'preferred approach', 'different paths', 'retail sales', '310bps context', 'tighter MoM', 'Euro Loans', 'capital structure', 'trading volumes', 'CCC-rated Loans', 'Cashflow generation', 'reduced cashflows', 'recent uptick', '15% target return', 'recent appreciation', 'positive impact', 'relevant NAVs', 'subordinated notes', 'asset classes', 'period ends', 'aggregate value', 'Olivier Pons', 'secondary market', 'date return', 'transition month', 'company earnings', 'annualized basis', 'overall performance', 'market activity', 'USD 60bn', 'risky assets', 'month-end date', 'NAV information', 'Portfolio Activity', 'VTA', 'RELEASE', 'PUBLICATION', 'WHOLE', 'THE', 'Guernsey', '19th', 'website', 'voltafinance', 'prices', 'terms', 'evidences', 'ECB', '25bps', 'Fed', 'Novembre', 'jurisdictions', 'employment', 'tailwind', 'Xover', 'issuance', 'Spreads', 'fundamentals', 'proportion', 'quarter', 'line', 'Q3', 'highs', 'result', 'interests', 'coupons', 'c.', 'SOFR', 'defaults', 'share', 'GAV', 'investments', 'policy', 'timely', '30 September', 'performances', 'Dietz-performance', 'bucket', 'account', 'changes', 'CONTACTS', '0.']",2024-11-19,2024-11-20,globenewswire.com
47104,EuroNext,NewsApi.org,https://www.irishtimes.com/business/2024/11/19/global-stocks-edge-lower-as-tensions-rise-between-us-and-russia/,Global stocks edge lower as tensions rise between US and Russia,Energy group Greencoat Renewables was the standout performer in Dublin as it climbed 2%  rebounding from recent lows,Traders work on the floor of the New York Stock Exchange. he S&P 500 and the tech-heavy Nasdaq edged higher  paring earlier losses as investors assessed Russia‚Äôs warning to the United States  and awaited quarterly results from AI-heavyweight Nvidia. Photograph: Angela Weiss/Getty ImagesGlobal stocks edged lower in choppy trading on Tuesday as markets awaited further appointments to the incoming White House administration  while oil prices eased as tensions rose between Russia and the United States over Ukraine.DublinEuronext Dublin closed down 1 per cent on what was a sluggish day for the market with limited volumes traded.One trader described it as ‚Äúrisk averse‚Äù day of trading  with few buyers around as investors eyed incoming results from chipmaker Nvidia in the United States after close of business.Energy group Greencoat Renewables was the standout performer in Dublin as it climbed 2 per cent  rebounding from recent lows.READ MOREOn the downside  agricultural services group Origin Enterprise finished the day down 2.8 per cent. Also finishing in the red was Ires Reit ‚Äì the biggest landlord in the State ‚Äì which sank 2 per cent.Among the financial names  AIB and Bank of Ireland were each down 1.5 per cent  while  elsewhere  insulation specialist Kingspan also closed down 1.5 per cent.LondonAcross the Irish Sea  stocks closed nearly flat after a choppy trading session  as investors avoided big bets ahead of a key inflation report.The export-focused FTSE 100 closed 0.11 per cent lower  while the midcap FTSE 250 index pared early losses and ended higher by 0.17 per cent  aided by utilities stocks. The midcaps index touched a three-month low during the session.The personal goods index led the declines with a 2.7 per cent fall  mostly affected by Burberry that slid 4.7 per cent. Mulberry Group fell 11 per cent after the luxury group reported a wider first-half loss than a year earlier  and said it was taking steps to streamline its operations and improve margins under new CEO Andrea Baldo.Imperial Brands rose 3 per cent after reporting forecast-beating operating profit and said it expected another strong performance next year. The stock was among the top gainers on the FTSE 100.Among others  Diploma‚Äôs shares fell 7.2 per cent to become the biggest loser on the blue chip index after the technical products and services provider missed annual revenue estimates.In contrast  Vesuvius‚Äôs shares rose 9.3 per cent to the top of the midcap index after the steel and foundry specialist launched a share buyback scheme.EuropeThe continent‚Äôs main stock index fell to a three-month low as investors shifted from risky assets to safe havens amid heightened geopolitical tensions following Russia‚Äôs warning on its updated nuclear doctrine.The pan-European Stoxx 600 dropped 0.7 per cent to its lowest level since early August. MSCI‚Äôs gauge of stocks across the globe was up slightly 0.15 per cent.‚ÄúThe market‚Äôs movement appears to be driven by this morning‚Äôs news about changes to Russia‚Äôs nuclear doctrine ‚Äù said Michael Weidner  co-head of global fixed income at Lazard Asset Management.New YorkThe S&P 500 and the tech-heavy Nasdaq edged higher  paring earlier losses as investors assessed Russia‚Äôs warning to the United States  and awaited quarterly results from AI-heavyweight Nvidia.Stocks had slid in early trading after Russian president Vladimir Putin lowered the threshold for a nuclear strike in response to a broader range of conventional attacks earlier in the day  and Moscow said Ukraine had struck deep inside Russia with US-made long-range missiles.All three major indexes opened lower and the benchmark index dropped as much as 0.64 per cent  while the Russell 2000 fell to its lowest since the US presidential election  as investors rushed to safe-haven assets such as government bonds and gold.Nvidia  which reports third-quarter results on Wednesday  gained 2.7 per cent  boosting the information technology sector that buoyed the benchmark S&P 500.Most megacap stocks such as Apple and Amazon also trended higher and lifted the Nasdaq.Meanwhile  healthcare shares weighed on the Dow. The losses were limited by a 3.6 per cent gain in retail giant Walmart that hit a record high after it raised its annual sales and profit forecasts for the third consecutive time. ‚Äì Additional reporting: Agencies,neutral,0.01,0.69,0.3,mixed,0.08,0.23,0.69,True,English,"['Global stocks', 'tensions', 'rise', 'US', 'Russian president Vladimir Putin', 'new CEO Andrea Baldo', 'incoming White House administration', 'New York Stock Exchange', 'key inflation report', 'wider first-half loss', 'share buyback scheme', 'Lazard Asset Management', 'three major indexes', 'US presidential election', 'information technology sector', 'retail giant Walmart', 'third consecutive time', 'personal goods index', 'blue chip index', 'forecast-beating operating profit', 'annual revenue estimates', 'global fixed income', 'main stock index', 'benchmark S&P 500', '2.7 per cent fall', '3.6 per cent gain', 'risk averse‚Äù day', 'agricultural services group', 'Most megacap stocks', 'The S&P 500', 'midcap FTSE 250 index', 'midcap index', 'benchmark index', 'incoming results', '0.17 per cent', '0.64 per cent', 'midcaps index', 'services provider', 'annual sales', 'profit forecasts', 'Energy group', 'Mulberry Group', 'luxury group', 'Global stocks', 'United States', 'quarterly results', 'Angela Weiss', 'Getty Images', 'oil prices', 'limited volumes', 'One trader', 'Greencoat Renewables', 'standout performer', 'recent lows', 'Origin Enterprise', 'Ires Reit', 'biggest landlord', 'financial names', 'insulation specialist', 'Irish Sea', 'big bets', 'export-focused FTSE 100', 'Imperial Brands', 'strong performance', 'biggest loser', 'technical products', 'foundry specialist', 'risky assets', 'safe havens', 'nuclear doctrine', 'pan-European Stoxx 600', 'lowest level', 'early August', 'Michael Weidner', 'nuclear strike', 'broader range', 'conventional attacks', 'long-range missiles', 'safe-haven assets', 'government bonds', 'third-quarter results', 'Additional reporting', 'earlier losses', 'AI-heavyweight Nvidia', 'sluggish day', 'chipmaker Nvidia', 'early losses', 'early trading', 'tech-heavy Nasdaq', 'utilities stocks', 'top gainers', 'geopolitical tensions', 'Euronext Dublin', 'healthcare shares', 'choppy trading', 'trading session', 'Traders', 'floor', 'investors', 'warning', 'Photograph', 'Tuesday', 'markets', 'appointments', 'Ukraine', 'buyers', 'close', 'business', 'READ', 'downside', 'red', 'AIB', 'Bank', 'Ireland', 'Kingspan', 'London', 'month', 'declines', 'Burberry', 'steps', 'operations', 'margins', 'others', 'Diploma', 'contrast', 'Vesuvius', 'steel', 'continent', 'updated', 'MSCI', 'gauge', 'globe', 'movement', 'morning', 'news', 'changes', 'head', 'threshold', 'response', 'Moscow', 'US-made', 'Russell', 'gold', 'Wednesday', 'Apple', 'Amazon', 'record', 'Agencies']",2024-11-19,2024-11-20,irishtimes.com
47105,EuroNext,Bing API,https://www.manilatimes.net/2024/11/21/tmt-newswire/globenewswire/nyxoah-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference/2008526,Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference,Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference,"Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare ConferenceMont-Saint-Guibert  Belgium - November 20  2024  10:05pm CET / 4:05pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (""Nyxoah‚Äù or the ""Company‚Äù)  a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation  today announced that the Company will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday  December 4  2024. The Company is scheduled to present at 2:00pm ET the same day via webcast.A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at investors.nyxoah.com.About NyxoahNyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio¬Æ  a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence  we have shown best-in-class outcomes for reducing OSA burden.Get the latest newsdelivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address  I acknowledge that I have read and agree to the Terms of Service and Privacy PolicyFollowing the successful completion of the BLAST OSA study  the Genio¬Æ system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study  Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients  currently contraindicated in competitors' therapy. Additionally  the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.Caution - CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.AdvertisementFORWARD-LOOKING STATEMENTSCertain statements  beliefs and opinions in this press release are forward-looking  reflecting Nyxoah's current expectations and beliefs regarding the Genio¬Æ system; planned and ongoing clinical studies of the Genio¬Æ system; the potential advantages of the Genio¬Æ system; Nyxoah's goals with respect to the development  regulatory pathway and potential use of the Genio¬Æ system; the utility of clinical data in potentially obtaining FDA approval of the Genio¬Æ system; and potential receipt of FDA approval and entrance into the U.S. market. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally  these risks and uncertainties include  but are not limited to  the risks and uncertainties set forth in the ""Risk Factors‚Äù section of Nyxoah's Annual Report on Form 20-F for the year ended December 31  2023  filed with the Securities and Exchange Commission (""SEC‚Äù) on March 20  2024  and subsequent reports that Nyxoah files with the SEC. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither Nyxoah nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.Contacts:NyxoahAdvertisementJohn Landry  CFO[email protected]For MediaIn United StatesAdvertisementFINN Partners - Glenn Silver[email protected]In Belgium/FranceAdvertisementBackstage Communication - Gunther De Backer[email protected]In International/GermanyMC Services - Anne HenneckeAdvertisement[email protected]Attachment",neutral,0.01,0.99,0.0,mixed,0.34,0.29,0.37,True,English,"['Piper Sandler 36th Annual Healthcare Conference', 'Nyxoah', 'Piper Sandler 36th Annual Healthcare Conference', 'DREAM IDE pivotal study', 'The Manila Times newsletters', 'U.S. commercialization approval', 'U.S. federal law', 'battery-free hypoglossal neuromodulation device', 'U.S. market', 'breakthrough treatment alternatives', 'investor relations page', 'European CE Mark', 'BETTER SLEEP study', 'CE mark approval', 'Obstructive Sleep Apnea', 'two successful IPOs', 'ongoing clinical studies', 'live audio webcast', 'BLAST OSA study', 'Risk Factors‚Äù section', 'medical technology company', 'Annual Report', 'Investigational device', 'The Company', 'successful completion', 'FDA approval', 'clinical evidence', 'clinical data', 'Euronext Brussels/Nasdaq', 'billion people', 'single incision', 'class outcomes', 'latest news', 'email address', 'Privacy Policy', 'positive outcomes', 'therapeutic indications', 'CCC) patients', ""competitors' therapy"", 'United States', 'investigational use', 'press release', 'potential advantages', 'regulatory pathway', 'potential use', 'potential receipt', 'financial effects', 'Exchange Commission', 'subsequent reports', 'subsidiary undertakings', 'actual occurrence', 'FORWARD-LOOKING STATEMENTS', 'Genio¬Æ system', 'other factors', 'future periods', 'OSA burden', '10:05pm CET', 'first innovation', 'current expectations', 'past trends', 'actual results', 'actual events', 'future performance', 'future accuracy', 'Nyxoah SA', '4:05pm', 'Mont-Saint-Guibert', 'Belgium', 'November', 'NYXH', 'Wednesday', 'December', '2:00pm', 'presentation', 'website', 'investors', 'chin', 'wearable', 'commitment', 'inbox', 'Terms', 'Service', 'September', 'July', 'expansion', 'Complete', 'Caution', 'Advertisement', 'beliefs', 'opinions', 'goals', 'respect', 'development', 'utility', 'entrance', 'nature', 'number', 'risks', 'uncertainties', 'assumptions', 'plans', 'year', 'Securities', 'March', 'multitude', 'changes', 'demand', 'competition', 'activities', 'guarantees', 'addition', 'warranties', 'fairness', 'obligation', 'updates', 'revisions', 'conditions', 'circumstances', 'regulation', 'advisers', 'representatives', 'person', 'officers', 'employees', 'errors', 'responsibility']",2024-11-21,2024-11-20,manilatimes.net
47106,EuroNext,Bing API,https://www.manilatimes.net/2024/11/21/tmt-newswire/globenewswire/availability-of-2024-2025-half-year-financial-report/2008471,Availability of 2024-2025 Half-Year Financial Report,- the statutory auditors' review report on the 2024-2025 half-yearly financial information. Q3'25 revenue is due to be published on February 5  2025  after market close.,AVAILABILITY OF 2024-2025 HALF-YEAR FINANCIAL REPORTBernin (Grenoble)  France  on November 20  2024 - Soitec (Euronext Paris)  a world leader in the design and manufacturing of innovative semiconductor materials  today announces that it has made available to the public and filed with the French Financial Markets Authority (Autorit√© des March√©s Financiers  or AMF) its 2024-2025 half-year financial report for the period ended on September 30  2024.The French and English version of the 2024-2025 half-year financial report is available for consultation on the Company's website www.soitec.com.Get the latest newsdelivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address  I acknowledge that I have read and agree to the Terms of Service and Privacy PolicyThe 2024-2025 half-year financial report includes:Advertisement- the condensed interim consolidated financial statements as of September 30  2024 - the 2024-2025 half-year activity report - the declaration by the person responsible for the half-year financial report  and- the statutory auditors' review report on the 2024-2025 half-yearly financial information.Advertisement# # #AgendaQ3'25 revenue is due to be published on February 5  2025  after market close.# # #AdvertisementAbout SoitecSoitec (Euronext - Tech Leaders)  a world leader in innovative semiconductor materials  has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France  Soitec is expanding internationally with its unique solutions  and generated sales of 1 billion Euros in fiscal year 2023-2024. Soitec occupies a key position in the semiconductor value chain  serving three main strategic markets: Mobile Communications  Automotive and Industrial  and Edge and Cloud AI. The company relies on the talent and diversity of its 2 300 employees  representing 50 different nationalities  working at its sites in Europe  the United States and Asia. Soitec has registered over 4 000 patents.Soitec  SmartSiC‚Ñ¢ and Smart Cut‚Ñ¢ are registered trademarks of Soitec.For more information: https://www.soitec.com/en/ and follow us on LinkedIn and X: @Soitec_OfficialAdvertisement# # #Investor Relations: [email protected] Advertisement Advertisement Media contact: Fabrice Baron +33 6 14 08 29 81 [email protected]# # #Attachment,neutral,0.0,1.0,0.0,positive,0.53,0.44,0.03,True,English,"['2024-2025 Half-Year Financial Report', 'Availability', 'Autorit√© des March√©s Financiers', 'three main strategic markets', 'interim consolidated financial statements', ""statutory auditors' review report"", '2024-2025 half-year activity report', 'HALF-YEAR FINANCIAL REPORT Bernin', '2024-2025 half-year financial report', 'French Financial Markets Authority', '2024-2025 half-yearly financial information', 'The Manila Times newsletters', 'Advertisement Advertisement Media contact', 'innovative semiconductor materials', 'semiconductor value chain', 'world leader', 'English version', 'latest news', 'email address', 'Privacy Policy', ""Q3'25 revenue"", 'Tech Leaders', 'cutting-edge products', 'technological performance', 'energy efficiency', 'global headquarters', 'unique solutions', '1 billion Euros', 'fiscal year', 'key position', 'Mobile Communications', 'Cloud AI', '50 different nationalities', 'United States', 'Smart Cut‚Ñ¢', 'Investor Relations', 'Fabrice Baron', 'Euronext Paris', 'AVAILABILITY', 'Grenoble', 'France', 'November', 'Soitec', 'design', 'manufacturing', 'public', 'AMF', 'period', 'September', 'consultation', 'Company', 'website', 'inbox', 'Terms', 'Service', 'condensed', 'declaration', 'person', 'Agenda', 'February', '30 years', 'sales', 'Automotive', 'Industrial', 'talent', 'diversity', '2,300 employees', 'sites', 'Europe', 'Asia', '4,000 patents', 'SmartSiC‚Ñ¢', 'trademarks', 'LinkedIn', 'Attachment']",2024-11-21,2024-11-20,manilatimes.net
47107,EuroNext,Bing API,https://markets.businessinsider.com/news/stocks/veon-s-kyivstar-acquires-new-spectrum-investing-uah-1-4-billion-in-ukraine-s-economy-1034042894,VEON‚Äôs Kyivstar Acquires New Spectrum  Investing UAH 1.4 Billion in Ukraine‚Äôs Economy,Kyivstar will invest UAH 1.43 billion (c. 34 million USD 1) in the Ukrainian economy through this spectrum acquisition. With this new acquisition  Kyivstar will boost its total spectrum holding from 152 MHz to 202 MHz  enabling it to retain the leading position among all private operators in Ukraine in terms of total amount of available spectrum.,"Amsterdam  Dubai and Kyiv  20 November 2024: VEON Ltd. (Nasdaq: VEON  Euronext Amsterdam: VEON)  a global digital operator (‚ÄúVEON‚Äù or the ‚ÄúGroup‚Äù)  announces that its wholly-owned subsidiary in Ukraine  Kyivstar  has successfully acquired 2x5 MHz spectrum in the 2100 MHz band and 40 MHz spectrum in the 2300 MHz band at an auction held by Ukraine‚Äôs National Commission for State Regulation of Electronic Communications  Radio Frequency Spectrum  and Postal Services (NCEC).Kyivstar will invest UAH 1.43 billion (c. 34 million USD1) in the Ukrainian economy through this spectrum acquisition. With this new acquisition  Kyivstar will boost its total spectrum holding from 152 MHz to 202 MHz  enabling it to retain the leading position among all private operators in Ukraine in terms of total amount of available spectrum.""We have consistently stated that the time to invest in Ukraine is now  and have committed 1 billion USD in investments through 2027. Today's spectrum acquisition is further proof that VEON  through its subsidiary Kyivstar  is here to walk the talk. We have an unwavering commitment to building Ukraine's digital infrastructure  taking 4G connectivity across the nation  bolstering our network‚Äôs energy resilience to keep Ukraine connected  and investing in the digital services that Ukraine needs "" said VEON Group CEO Kaan Terzioglu.Kyivstar is the 100%-owned subsidiary of VEON. Forbes Ukraine and New Voice of Ukraine have previously named Kyivstar the fifth largest investor in Ukraine over 2022-2023  making VEON the country‚Äôs largest foreign investor during that period. Kyivstar has over 23 million mobile subscribers and over 1 million home internet subscribers; it provides digital healthcare services to more than 28 million registered patients and 1 600 healthcare institutions through Helsi; and serves 1.6 million monthly active users with Ukraine‚Äôs leading infotainment platform KyivstarTV.1 National Bank of Ukraine official exchange rated as at 19.11.2024: 41.3715 UAH/USDAbout KyivstarKyivstar is the largest telecoms operator in Ukraine with over 23 million mobile subscribers and over 1 million home internet subscribers. As Ukraine‚Äôs market-leading operator  the company maintained network availability above 90% level on average since February 2022  supporting the connectivity of not only its own customers but also the broader Ukrainian population. Kyivstar is 100% owned by VEON Group.About VEONVEON is a global digital operator provides converged connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world's population  VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on Nasdaq and Euronext. For more information visit: https://www.veon.com.DisclaimerThis release contains ‚Äúforward-looking statements ‚Äù as the phrase is defined in Section 27A of the U.S. Securities Act of 1933  as amended  and Section 21E of the U.S. Securities Exchange Act of 1934  as amended. Forward-looking statements are not historical facts  and include statements relating to  among other things  VEON‚Äôs commercial and investment plans. Forward-looking statements are inherently subject to risks and uncertainties  many of which VEON cannot predict with accuracy and some of which VEON might not anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update  except as required by U.S. federal securities laws  any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events.VEONHande AsikGroup Director of Communicationspr@veon.com",neutral,0.0,1.0,0.0,negative,0.0,0.07,0.93,True,English,"['New Spectrum', 'UAH 1.4 Billion', 'VEON', 'Kyivstar', 'Ukraine', 'Economy', 'U.S. federal securities laws', 'U.S. Securities Exchange Act', 'U.S. Securities Act', '1.6 million monthly active users', '1 million home internet subscribers', 'Hande Asik Group Director', '23 million mobile subscribers', '28 million registered patients', 'largest telecoms operator', 'leading infotainment platform', 'Radio Frequency Spectrum', 'global digital operator', 'Ukraine official exchange', 'largest foreign investor', 'broader Ukrainian population', 'digital healthcare services', '2x5 MHz spectrum', 'VEON Group CEO', '160 million customers', 'market-leading operator', 'digital services', 'Ukrainian economy', 'leading position', 'digital infrastructure', '1,600 healthcare institutions', 'spectrum acquisition', 'total spectrum', 'available spectrum', 'Postal Services', 'technology-driven services', '40 MHz spectrum', 'National Commission', 'State Regulation', 'new acquisition', 'private operators', 'total amount', '1 billion USD', 'unwavering commitment', 'energy resilience', 'Kaan Terzioglu', 'New Voice', '1 National Bank', 'six countries', 'economic growth', 'Section 27A', 'Section 21E', 'historical facts', 'other things', 'investment plans', 'looking statement', '2100 MHz band', '2300 MHz band', '4G connectivity', 'converged connectivity', 'Electronic Communications', 'network availability', 'unanticipated events', '100%-owned subsidiary', 'Forbes Ukraine', 'VEON Ltd.', 'Euronext Amsterdam', '152 MHz', '202 MHz', 'statements', 'Dubai', 'Kyiv', 'Nasdaq', 'auction', 'NCEC', 'UAH', 'terms', 'time', 'investments', 'proof', 'talk', 'country', 'period', 'Helsi', 'company', '90% level', 'February', 'world', 'lives', 'individuals', 'information', 'Disclaimer', 'release', 'phrase', 'commercial', 'risks', 'uncertainties', 'accuracy', 'date', 'forward', 'circumstances', 'occurrence']",2024-11-20,2024-11-20,markets.businessinsider.com
47108,EuroNext,Bing API,https://www.di.se/pressreleaser/2024/11/20/akobo-minerals-ab-akobo-minerals-and-ethiopian-prime-minister-abiy-ahmed-inaugurate-the-segele-mine/,Akobo Minerals and Ethiopian Prime Minister Abiy Ahmed inaugurate the Segele Mine,OSLO  20 November 2024 ‚Äî Akobo Minerals AB (publ) (Euronext and Frankfurt: AKOBO) a Scandinavian-based Ethiopian gold exploration and mining company  in collaboration with the Ethiopian government  proudly announces the official inauguration of the ...,"OSLO  20 November 2024 ‚Äî Akobo Minerals AB (publ) (Euronext and Frankfurt: AKOBO) a Scandinavian-based Ethiopian gold exploration and mining company  in collaboration with the Ethiopian government  proudly announces the official inauguration of the Segele mine by His Excellency Prime Minister Abiy Ahmed. Adding to the excitement of the day was the gold pour  a symbolic act overseen by Prime Minister Abiy. The gold pour yielded an impressive 6.5 kilograms  a shining example of the mine's high-grade ore and production capabilities.The inauguration ceremony brought together key dignitaries and Akobo Minerals staff to celebrate this remarkable achievement. Prime Minister Abiy Ahmed  accompanied by Gambella Region President Ms. Alemitu Umod and Minister of Mines Habtamu Tegegne  toured the state-of-the-art Segele mine facility  observing its innovative technologies and efficient operations. The Prime Minister delivered an inspiring speech  highlighting the transformative potential of the mine for Ethiopia's economic diversification and the empowerment of local communities.""The Segele mine is a testament to Ethiopia's vast potential in the mining sector and the importance of international partnerships to realize this potential "" said Prime Minister Abiy. ""We are proud to see this project reach a significant milestone  benefiting not only the national economy but also the communities around it.""Akobo Minerals CEO J√∏rgen Evjen shared heartfelt words of gratitude during his address  applauding the tireless efforts of the Akobo Minerals and Etno Mining teams in preparing for this momentous day.""The inauguration of the Segele mine is a defining moment for Akobo Minerals. This project is the result of years of dedication  collaboration  and innovation "" Evjen said. ""We are especially grateful to the Ethiopian government  the Gambella region  and the local community for their unwavering support. Together  we have built something truly extraordinary.""Gambella Region President Ms. Alemitu Umod also addressed the gathering  emphasizing the regional benefits of the Segele mine  including job creation  improved infrastructure  and enhanced opportunities for local communities. She expressed her gratitude to Akobo Minerals for their commitment to the region's growth and development.The Segele mine  located in the Gambella region  represents a landmark in Ethiopian gold exploration and production. With its high-grade ore body and innovative processing methods  the mine is poised to contribute to Ethiopia's export revenues and local employment opportunities. Akobo Minerals has invested extensively in its exploration and mining operations and community development initiatives  including local job creation  supporting local education  improving healthcare  and enhancing infrastructure  to ensure the project's long-term success and positive impact on the surrounding area.For more information  contactJ√∏rgen Evjen  CEO Akobo MineralsMob: +47 92 80 40 14Mail: jorgen@akobominerals.comLinkedIn: www.linkedin.com/company/akobomineralswww.akobominerals.comAbout Akobo MineralsAkobo Minerals is a Scandinavian-based gold exploration and mining company  currently holding an exploration license covering 182 km2 and a mining license covering 16 km2 in the Gambela region and Dima Woreda  Ethiopia. With over 14 years of active operations on the ground  the company has established a strong foothold in Ethiopian gold exploration  now further strengthened with the startup of its Segele mine.Akobo Minerals‚Äô Segele mine has an Inferred and Indicated Mineral Resource of 68 000 ounces  yielding a world-class gold grade of 22.7 g/ton The mineralized zone remains open at depth  supporting future resource estimates and extending the mine‚Äôs life. The exploration license holds numerous promising exploration resource-building prospects in both the vicinity of Segele and in the wider license area.Akobo Minerals maintains strong relationships with local communities and government authorities  placing ESG principles at the core of its operations. The company‚Äôs commitment to sound ethics  transparency  and stakeholder engagement is evident through its industry-leading extended shared value program.Akobo Minerals is ready to take on new opportunities and ventures as they arise. The company is uniquely positioned to become a major player in the future development of the very promising Ethiopian mining industry.The company is headquartered in Oslo and is publicly listed on the Euronext Growth Oslo Exchange and the Frankfurt Stock Exchange under the ticker symbol AKOBO. For US investors  Akobo Minerals AB (OTCQX: AKOBF) is traded on the OTCQX Best Market  adhering to high financial standards  best practice corporate governance  and compliance with U.S. securities laws. Additionally  the company has a professional third-party sponsor introduction  and investors can access current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com .Akobo Minerals places great emphasis on meeting and exceeding industry standards  fully complying with all aspects of the JORC code  2012. For detailed information on their adherence to this code  please refer to https://www.jorc.org/. Akobo Minerals' unwavering commitment to ethical practices  community engagement  and environmental responsibility positions them as a formidable force in the evolving landscape of the Ethiopian mining sector.Se fullst√§ndigt pressmeddelande och andra nyheter fr√•n detta bolag p√• Cision News.Vill du ocks√• synas med dina nyheter p√• Di.se?L√§s mer om publicering p√• Di.se",neutral,0.01,0.99,0.0,positive,0.85,0.15,0.0,True,English,"['Ethiopian Prime Minister Abiy Ahmed', 'Akobo Minerals', 'Segele Mine', 'industry-leading extended shared value program', 'Akobo Minerals CEO J√∏rgen Evjen', 'numerous promising exploration resource-building prospects', 'Excellency Prime Minister Abiy Ahmed', 'U.S. securities laws', 'professional third-party sponsor introduction', 'CEO Akobo Minerals Mob', 'promising Ethiopian mining industry', 'art Segele mine facility', 'Scandinavian-based Ethiopian gold exploration', 'Euronext Growth Oslo Exchange', 'Akobo Minerals‚Äô Segele mine', 'The Prime Minister', 'Ms. Alemitu Umod', 'Mines Habtamu Tegegne', 'Indicated Mineral Resource', 'high financial standards', 'current financial disclosures', 'Real-Time Level 2 quotes', 'Scandinavian-based gold exploration', 'world-class gold grade', 'innovative processing methods', 'future resource estimates', 'Frankfurt Stock Exchange', 'Etno Mining teams', 'Akobo Minerals AB', 'Akobo Minerals staff', 'high-grade ore body', 'wider license area', 'The Segele mine', 'Gambella Region President', 'community development initiatives', 'OTCQX Best Market', 'local employment opportunities', 'local job creation', 'industry sta', 'exploration license', 'Ethiopian government', 'local community', 'mining license', 'gold pour', 'innovative technologies', 'surrounding area', 'future development', 'best practice', 'mining sector', 'local education', 'mining operations', 'Gambela region', 'local communities', 'symbolic act', 'impressive 6.5 kilograms', 'shining example', 'key dignitaries', 'remarkable achievement', 'inspiring speech', 'economic diversification', 'international partnerships', 'significant milestone', 'national economy', 'heartfelt words', 'tireless efforts', 'defining moment', 'unwavering support', 'regional benefits', 'export revenues', 'long-term success', 'positive impact', 'Dima Woreda', 'strong foothold', 'mineralized zone', 'strong relationships', 'government authorities', 'ESG principles', 'sound ethics', 'stakeholder engagement', 'new opportunities', 'major player', 'ticker symbol', 'corporate governance', 'great emphasis', 'efficient operations', 'active operations', 'mining company', 'official inauguration', 'inauguration ceremony', 'transformative potential', 'vast potential', 'production capabilities', 'momentous day', 'US investors', 'collaboration', 'His', 'excitement', 'state', 'empowerment', 'testament', 'importance', 'project', 'gratitude', 'address', 'result', 'years', 'dedication', 'innovation', 'something', 'gathering', 'infrastructure', 'commitment', 'landmark', 'healthcare', 'information', 'contact', 'Mail', 'jorgen', 'akobominerals', 'LinkedIn', '182 km2', '16 km2', 'ground', 'startup', 'Inferred', '68,000 ounces', '22.7 g', 'depth', 'life', 'vicinity', 'core', 'transparency', 'ventures', 'AKOBF', 'compliance', 'otcmarkets', 'meeting']",2024-11-20,2024-11-20,di.se
47109,EuroNext,Bing API,https://www.pharmiweb.com/press-release/2024-11-20/onward-medical-awarded-grant-to-study-potential-for-arc-bci-therapy-to-restore-movement-after-stroke,ONWARD Medical Awarded Grant to Study Potential for ARC-BCI Therapy to Restore Movement after Stroke,ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative spinal cord stimulation therapies to restore movement  function  and independence in people with spinal cord injury (SCI) ,"Grant supports the first clinical trials studying the potential for brain-computer interface (BCI) and artificial intelligence (AI) technology to restore thought-driven movement after strokeFunding also supports technology development of ARC-BCI System and ARC-IM LeadApproximately 15 million people worldwide experience a stroke each yearEINDHOVEN  the Netherlands  Nov. 19  2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative spinal cord stimulation therapies to restore movement  function  and independence in people with spinal cord injury (SCI)  today announces a grant from the European Innovation Council (EIC) to study the use of its investigational ARC-BCI Therapy to restore upper limb movement after subcortical stroke.""While helping people with spinal cord injury remains our North Star  this grant underscores the potential for our breakthrough therapies to impact people with other movement disabilities  such as stroke "" said Dave Marver  CEO of ONWARD Medical. ""The funding supports next steps in developing what may be the first-ever therapy to restore thought-driven hand and arm function after stroke.""This is the third EIC grant supporting the development of ARC-BCI Therapy to address movement challenges  and the first targeting stroke; the first two grants were SCI-focused. The Company‚Äôs research and technology partners in the grant consortium include Commissariat √† L'√©nergie Atomique et aux √ânergies Alternatives (CEA) and Dessintey of France  Department of Clinical Sciences  KI DS  Karolinska Institutet  of Sweden  √âcole Polytechnique F√©d√©rale de Lausanne (EPFL) and Centre Hospitalie Universitaire Vaudois (CHUV) of Switzerland.Total expected funding over five years from this grant and companion funding from the Swiss State Secretariat for Education  Research  and Innovation (SERI) is EUR 6 million with ONWARD receiving almost EUR 2 million.The Company plans to use this funding to develop the capability to program and simultaneously control two investigational ARC-IM IPGs (implanted neurostimulators)  and to further develop its ARC-IM Lead for the cervical spinal cord  the spinal cord region responsible for upper extremity function.To date  three trial participants have been implanted with ONWARD ARC-BCI Therapy. The first human use of ARC-BCI Therapy for lower limb mobility occurred in 2021  with results published in Nature in May 2023. In the fall of 2023  an individual was implanted to explore the potential for ARC-BCI Therapy to restore upper extremity function after SCI. In the fall of 2024  a third trial participant was implanted to study the potential for ARC-BCI Therapy to restore lower limb mobility after SCI. Several additional ARC-BCI System implants are expected in 2025  with grant support from the Christopher & Dana Reeve Foundation.The ONWARD ARC-BCI System pairs the WIMAGINE BCI with investigational ONWARD ARC-IM Therapy (targeted implanted spinal cord stimulation) to create a DigitalBridge‚Ñ¢  facilitating communication between the brain and the body with a wireless BCI to restore thought-driven movement after paralysis. The ARC-BCI System uses AI to decode a person‚Äôs brain signals and translate their intention into thought-driven movement. The WIMAGINE BCI has seven years of human safety data  and ONWARD ARC-IM Therapy has now been applied in more than 30 study participants. The US FDA awarded Breakthrough Device Designation to the ARC-BCI System in early 2024  one of 10 such designations awarded to the Company.About 15 million people worldwide experience a stroke each year  of which nearly four million are subcortical  according to the World Stroke Organization and American Heart Association.Note: All ONWARD Medical devices and therapies  including but not limited to ARC-IM  ARC-EX  ARC-BCI  and ARC Therapy  alone or in combination with a brain-computer interface (BCI)  are investigational and not available for commercial use. ONWARD  ARC-EX  ARC-IM  ARC-BCI  and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.About ONWARD MedicalONWARD Medical is a medical technology company creating therapies to restore movement  function  and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery  preclinical  and clinical research conducted at leading hospitals  rehabilitation clinics  and neuroscience laboratories  the Company has developed ARC Therapy  which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA).ONWARD ARC Therapy is targeted  programmed spinal cord stimulation designed to be delivered by the Company‚Äôs external ARC-EX or implantable ARC-IM platforms. ARC Therapy can also be delivered by the Company‚Äôs ARC-BCI platform  which pairs the ARC-IM System with brain-computer interface (BCI) technology to restore movement after SCI with thought-driven control.Use of non-invasive ARC-EX Therapy significantly improved upper limb function after SCI in the global pivotal Up-LIFT trial  with results published by Nature Medicine in May 2024. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in Europe. In parallel  the Company is conducting clinical studies with its ARC-IM Therapy  which demonstrated positive interim clinical outcomes for improved blood pressure regulation following SCI. Other ongoing clinical studies focus on using ARC-IM Therapy to address mobility after SCI and gait challenges in Parkinson‚Äôs disease as well as using the ARC-BCI platform to restore thought-driven movement of both upper and lower limbs after SCI.Headquartered in Eindhoven  the Netherlands  ONWARD Medical has a Science and Engineering Center in Lausanne  Switzerland  and a US office in Boston  Massachusetts. The Company is listed on Euronext Paris  Brussels  and Amsterdam (ticker: ONWD).For more information  visit ONWD.com  and connect with us on LinkedIn and YouTube.For Media Inquiries:Aditi Roy  VP Communicationsmedia@onwd.comFor Investor Inquiries:Amori Fraser  Finance Directorinvestors@onwd.comDisclaimerCertain statements  beliefs  and opinions in this press release are forward-looking  which reflect the Company‚Äôs or  as appropriate  the Company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve several risks  uncertainties  and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  delays in regulatory approvals  changes in demand  competition  and technology  can cause actual events  performance  or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions  or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release. All ONWARD Medical devices and therapies referenced here  including but not limited to ARC-IM  ARC-EX  ARC-BCI and ARC Therapy  are investigational and not available for commercial use.",neutral,0.01,0.99,0.0,mixed,0.33,0.35,0.33,True,English,"['ONWARD Medical', 'ARC-BCI Therapy', 'Grant', 'Potential', 'Movement', 'Stroke', '√âcole Polytechnique F√©d√©rale', 'Several additional ARC-BCI System implants', 'innovative spinal cord stimulation therapies', 'Centre Hospitalie Universitaire Vaudois', 'two investigational ARC-IM IPGs', 'ONWARD Medical N.V.', 'ten Breakthrough Device Designations', 'investigational ONWARD ARC-IM Therapy', 'The ONWARD ARC-BCI System', 'spinal cord injury', 'cervical spinal cord', 'spinal cord region', 'first two grants', 'Swiss State Secretariat', 'lower limb mobility', 'third trial participant', 'Dana Reeve Foundation', 'human safety data', 'American Heart Association', 'investigational ARC-BCI Therapy', 'three trial participants', 'implantable ARC-IM platforms', 'ONWARD Medical devices', 'The ARC-BCI System', 'European Innovation Council', 'first clinical trials', 'upper extremity function', 'World Stroke Organization', 'upper limb movement', 'ONWARD ARC-BCI Therapy', 'invasive ARC-EX Therapy', 'other movement disabilities', 'first human use', 'first targeting stroke', 'ONWARD ARC Therapy', 'The US FDA', 'The WIMAGINE BCI', 'medical technology company', 'third EIC grant', 'ARC-IM System', 'breakthrough therapies', '30 study participants', 'US Food', 'ARC-IM Lead', 'ARC-BCI platform', 'technology partners', 'Clinical Sciences', 'The Company', 'BCI) technology', 'brain-computer interface', 'artificial intelligence', 'GLOBE NEWSWIRE', 'North Star', 'Dave Marver', 'next steps', 'thought-driven hand', 'arm function', '√©nergie Atomique', '√ânergies Alternatives', 'KI DS', 'Karolinska Institutet', 'five years', 'seven years', 'stylized O-Logo', 'registered trademarks', 'a decade', 'scientific discovery', 'leading hospitals', 'rehabilitation clinics', 'neuroscience laboratories', 'Drug Administration', 'external ARC-EX', 'driven control', 'thought-driven movement', 'movement challenges', 'AI) technology', 'technology development', 'wireless BCI', 'commercial use', 'Unauthorized use', 'subcortical stroke', 'clinical research', 'grant consortium', 'grant support', 'brain signals', 'companion funding', '15 million people', 'stroke Funding', 'potential', 'EINDHOVEN', 'Netherlands', 'Euronext', 'ONWD', 'independence', 'CEO', 'Commissariat', 'CEA', 'Dessintey', 'France', 'Department', 'Sweden', 'Lausanne', 'EPFL', 'CHUV', 'Switzerland', 'Total', 'Education', 'SERI', 'capability', 'neurostimulators', 'date', 'results', 'Nature', 'May', 'fall', 'individual', 'SCI.', 'Christopher', 'targeted', 'DigitalBridge‚Ñ¢', 'communication', 'body', 'paralysis', 'person', 'intention', 'early 2024', 'Note', 'combination', 'proprietary', 'preclinical', 'non', '10']",2024-11-20,2024-11-20,pharmiweb.com
